



 Chronic Kidney 
Disease: Comparing 
Trends in Primary 
and Secondary Care 
Masters by Research Thesis 
 
Alexandria Waldron 






I would like to offer my deepest appreciation to everyone who has been involved in the 
writing of my thesis. I would like to thank my supervisors Professor Peter Diggle, Dr Aimun 
Ahmed and Dr Simon Wetherall for their support and guidance throughout my project; 
especially Professor Peter Diggle whose expert knowledge of statistics and patient teaching 
made this project possible. I must also express my gratitude to Yvonne Bailey and Andrew 
Livesey for their assistance with data collection.  
Finally I would like to extend my thanks to my friends and family without whom I surely 
would have lost my sanity somewhere along the way. Thank you for your support and 



















Chapter 1: Introduction...................................................................................................... 7 
1.1. Definition of Chronic Kidney Disease..................................................... 7 
1.2. Classification of Chronic Kidney Disease................................................ 7 
1.3. Epidemiology of Chronic Kidney Disease............................................... 9 
1.3.1. Incidence and Prevalence of CKD................................................... 9 
1.3.2. Incidence and Prevalence of End-stage Renal Disease ................. 11 
1.4. Global Burden of CKD and its Complications ........................................ 12 
1.4.1. Vascular Risk.................................................................................. 13 
1.4.2. Anaemia......................................................................................... 14 
1.4.3. Metabolic Acidosis and Metabolic Bone Disease........................... 16 
1.4.4. Volume Overload........................................................................... 17 
1.4.5. Electrolyte Disturbances................................................................ 18 
1.4.6. Vitamin D and Secondary Hyperparathyroidism............................ 19 
1.5. Evolution of Relevant CKD Guidelines.................................................... 20 
1.5.1. Who should be tested?................................................................... 20 
1.5.2. Classification................................................................................... 22 
1.5.3. Frequency of Monitoring................................................................ 22 
1.5.4. Defining Progression....................................................................... 24 
1.5.5. Risk Factors..................................................................................... 26 
1.5.6. Blood Pressure Control................................................................... 27 
1.5.7. Reducing Cardiovascular Risk.......................................................... 30 
1.5.8. Bone Metabolism, Osteoporosis and CKD-MBD............................. 31 
3 
 
1.5.9. Anaemia........................................................................................ 33 
1.5.10. Metabolic Acidosis.................................................................... 34 
1.6. Referral Criteria to Secondary Care...................................................... 34 
1.7. Summary............................................................................................... 36 
Chapter 2: Chronic Kidney Disease Progression................................................................ 37 
2.1. Risk Factors for CKD Progression.......................................................... 37 
2.1.1. Diabetes........................................................................................ 37 
2.1.2. Hypertension................................................................................ 38 
2.1.3. Vascular Disease........................................................................... 40 
2.1.4. Proteinuria.................................................................................... 41 
2.2. Slowing Progression of CKD.................................................................. 42 
2.2.1. Glycaemic Control......................................................................... 42 
2.2.2. Managing Hypertension................................................................ 43 
2.2.3. Reducing Cardiovascular Risk........................................................ 46 
2.2.4. Proteinuria Reduction................................................................... 47 
2.3. Impact of Secondary Care Referral....................................................... 47 
2.3.1. Secondary Care and Progression Rates......................................... 47 
2.3.2. Timing of Secondary Care Referral................................................ 49 
2.3.3. Duration and Frequency of Secondary Care.................................. 50 
2.4. Summary................................................................................................ 51 
Chapter 3: Objectives....................................................................................................... 53 
3.1. General Aim........................................................................................... 53 
3.2. Specific Objectives................................................................................. 53 
Chapter 4: Methods......................................................................................................... 54 
4.1. Data Sources........................................................................................... 54 
4.2. Entry Criteria........................................................................................... 54 
4 
 
4.3. Manual Data Collection........................................................................... 55 
4.4. Reformatting........................................................................................... 56 
4.5. Statistical Software................................................................................. 57 
4.6. Simple Linear Modelling......................................................................... 57 
4.7. Multiple Linear Regression..................................................................... 59 
4.8. Linear Mixed Effects Modelling.............................................................. 60 
4.9. Residual Analysis.................................................................................... 61 
4.10. Likelihood............................................................................................. 62 
Chapter 5: Cross-sectional Analysis Results...................................................................... 63 
5.1. Description of the Study Population....................................................... 63 
5.2. Simple Linear Modelling of Continuous Variables.................................. 68 
5.3. Simple Linear Modelling of Categorical Variables................................... 70 
5.4. Multiple Linear Regression Modelling.................................................... 72 
Chapter 6: Longitudinal Analysis Results.......................................................................... 78 
6.1. Description of Longitudinal Data............................................................ 78 
6.2. Preliminary Linear Mixed Effects Modelling........................................... 80 
6.3. Final Mixed Effects Modelling................................................................. 83 
6.4. Residual Diagnostics................................................................................ 87 
6.5. Patient Mortality, Progression to ESRD and Initiation of RRT................. 88 
6.6. Summary................................................................................................. 89 
Chapter 7: Discussion and Conclusions............................................................................. 91 
7.1. Discussion................................................................................................ 91 
7.2. Clinical Impact......................................................................................... 99 
7.3. Limitations of the Study.......................................................................... 101 
7.4. Suggestions for Further Research........................................................... 103 




Appendix A – Figures and Tables.................................................................................... 122 




























Chronic kidney disease is a serious and complex medical condition which affects a significant 
number of people in the UK. Guidance from NICE currently recommends referral of CKD 
patients at stages G4-5 but the guidelines themselves are not based on strong evidence. 
Objectives 
To compare progression rates for CKD G3 patients in primary and secondary care groups to 
determine whether or not earlier referral should be supported. 
Methods 
We categorised 1,345 patients with stage G3 CKD into primary and secondary care and 
further subdivided secondary care into non-renal and renal groups. Baseline differences 
between primary and secondary care groups were explored via Student t-tests and chi-
squared analyses. Baseline exploratory analysis of potential relationships between eGFR and 
other variables was done via simple linear and multiple regression modelling. Longitudinal 
trends were described using linear mixed effects modelling and chi-squared tests were used 
to compare differences in all-cause mortality and end-stage renal disease rates. 
Results 
The overall trend was an improvement in renal function by 1.26 ml/min/1.73 m2 per year 
over an average follow up period of 2.84 years. Trends for primary, non-renal secondary and 
renal secondary care were 1.84, 0.87 and -0.17 ml/min/1.73 m2 per year respectively. The 
relative risk of all-cause mortality was 2.49 times greater for secondary care patients 
compared to primary care (p<0.001). 
Conclusions 
The management of CKD G3 patients in primary care is able to defer renal decline for at least 
2.84 years. Most patients who are at higher risk of progression are already identified and 







CHAPTER 1: INTRODUCTION 
 
This chapter aims to introduce and explore the literature surrounding stage 3 chronic kidney 
disease (CKD) especially with regards to the impact that the condition has on health. We 
then investigate the evidence underpinning UK guidelines on CKD in order to outline our 
rationale that the evidence underpinning them, especially those relating to referral, is poor 
and that research on which care setting is best for stage 3 CKD patients is currently lacking. 
 
1.1 Definition of Chronic Kidney Disease 
Chronic kidney disease, previously known as chronic renal failure or chronic renal 
insufficiency, is defined as “abnormalities of kidney structure or function, present for more 
than 3 months, with implications for health”1. This is the international definition first used by 
the Kidney Disease Improving Global Outcomes (KDIGO) initiative in 2012 and that which is 
currently used by the National Institute of Clinical Excellence (NICE)1,2. It encompasses all 
people identified as having a glomerular filtration rate (GFR) below 60 ml/min/1.73 m2 on 
more than one occasion separated by a minimum of 90 days plus anyone with markers of 
kidney damage regardless of their GFR measurements. 
 
1.2 Classification of Chronic Kidney Disease 
CKD is classified into categories by both glomerular filtration rate (GFR) and albumin to 
creatinine ratio (ACR) into five and three groups respectively1,2. 
GFR category, denoted by the letter ‘G’, has thresholds ranging from ≥ 90 ml/min/1.73 m2 
for G1 to < 15 ml/min/1.73 m2 for G5. As mentioned above, the threshold for diagnosis in 
the absence of additional markers of kidney damage is 60 ml/min/1.73 m2; below which 
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people would fall into a classification of G3, G4 or G5. Category G3 has been further 
subdivided into 3a (GFR 45-59 ml/min/1.73m2) and 3b (30-44 ml/min/1.73m2) to underline 
the higher risk of adverse outcomes for those in the latter category. For those with a 
classification of G1 or G2, additional markers of kidney disease must be present. Accepted 
markers include ‘albuminuria (ACR more than 3 mg/mmol), urine sediment abnormalities, 
electrolyte and other abnormalities due to tubular disorders, abnormalities detected by 
histology, structural abnormalities detected by imaging, and a history of kidney 
transplantation.’ 
As more accurate measurements of GFR are not practical in every day clinical practice, 
estimated GFR (eGFR) values calculated from serum creatinine measurements are usually 
used to categorise patients instead. Table 1 outlines the full classification by GFR below. 
Table 1: GFR Categories in CKD (KDIGO Classification) 
GFR Category GFR (ml/min/1.73 m2) Terms 
G1 ≥ 90 Normal or high 
G2 60-89  Mildly decreased 
G3a 45-59  Mildly to moderately decreased 
G3b 30-44 Moderately to severely decreased 
G4 15-29  Severely decreased 
G5 < 15  Kidney failure 
 
 
ACR category, denoted by the letter ‘A’ was introduced into international classification 
system in 2012 by KDIGO. This classification by ACR ranges from A1 (ACR < 3 mg/mmol) to 
A3 (> 30 mg/mmol) and allows patients to be delineated by increasing albuminuria and 
therefore by increasing risk of CKD progression. Table 2 outlines the categorisation by ACR 
and its equivalent investigation results below. 





ACR  (approximate equivalent) 
(mg/mmol)                 (mg/g) 
 
Terms 
A1 < 30 < 3 < 30 Normal to mildly increased 
A2 30-300 3-30 30-300 Moderately increased 
A3 > 300 > 30 > 300 Severely increased 
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1.3 Epidemiology of Chronic Kidney Disease 
1.3.1 Incidence and Prevalence of CKD 
The narrative of chronic kidney disease is frequently described as ‘silent’ in the early stages 
of the disease, with cases of CKD often identified opportunistically from routine blood tests 
as opposed to the specific investigation of symptomatic patients. The most common cause 
of CKD worldwide is diabetes mellitus so it is no surprise that for CKD some of the highest 
prevalence rates are often found in more developed countries such as the USA3. More than 
20,000,000 Americans have CKD which is equivalent to more than 10% of the population 
with suggested rates estimated to be as high as 16.8%4. Similar figures have been 
determined in UK populations with 13% of the total population estimated to have CKD 
stages 3-55. There is strong evidence showing rising CKD prevalence in the USA from 1988-
1994 to 1999-2006; which may be explained in part by increasing prevalence rates of 
diabetes mellitus and hypertension6. However, figures from the National Health and 
Nutrition Examination Survey (NHANES) 2007-2012 and from the Health Survey for England 
(HSE) 2010 support an overall reduction in prevalence rates for America and the UK in more 
recent years4,5 and for all subgroups by age and sex with the exception of the subgroup of 
men aged 65-74 years old whose prevalence increased5. Despite this small improvement in 
prevalence figures, CKD still presents a large problem with regards to its undiagnosed 
burden of disease7. In the UK only 4.3% of UK adults had a diagnosis of CKD in 2010-20138,9 
which when compared to the aforementioned 13% estimated prevalence rate is an 
underdiagnosis of almost 9%. This may have future implications especially given the 
expected rise in global CKD prevalence from predictions of the increasing prevalence of risk 
factors such as diabetes, hypertension and cardiovascular disease in developing countries3. 
There are several demographic risk factors which influence the likelihood of developing 
chronic kidney disease including age, sex and ethnicity. Cross-sectional studies have 
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demonstrated that prevalence of CKD increases exponentially with age6,10,11, which has 
prompted debate over whether or not chronic kidney disease is a pathological phenomenon 
or is conversely a resulting part of the normal ageing process. However regardless, this 
association between increasing age and increasing CKD prevalence is important in light of an 
ageing population which is likely to increase the existing burden of chronic kidney disease. 
Prevalence of chronic kidney disease is higher overall in women compared to men with an 
estimated 25% of women and 20% of men aged 65-74 thought to have CKD worldwide. The 
most recent figures from the UK show a 1% difference in prevalence between men and 
women demonstrated by figures of 6% and 7% for men and women respectively5. On the 
other hand, the relationship between ethnicity and CKD development is not as clear cut. 
Compared to white populations, non-white ethnic groups have lower or similar prevalence 
rates of CKD but may be at higher risk of progressive disease or adverse renal events12. This 
is especially true for black ethnic groups and may be explained by genetic differences 
between different races or linked to other confounding factors such as socioeconomic status 
and reduced access to healthcare12–15. 
The relationship between smoking status and CKD has been better researched and 
documented than for other lifestyle factors. There is good evidence to support cigarette 
smoking as a risk factor for developing CKD in both diabetic and non-diabetic patients16–18. 
The relative risk of CKD development for current smokers compared to the total population 
is 2.5 times higher and has been shown to have an attributable risk of 31% according to a 
prospective study in 200316.  In patients with type 2 diabetes the underlying mechanism for 
increasing CKD development risk in smokers is linked to the development of 
microalbuminuria. This has been independently and significantly associated with CKD 




1.3.2 Incidence and Prevalence of End-Stage Renal Disease 
End-stage renal disease (ESRD), a term used synonymously with renal failure, is the final 
stage in CKD and quantitatively refers to when GFR falls below 15 ml/min/1.73 m2. It marks a 
patient’s necessity for life-saving renal replacement therapy (RRT) in the interim period 
before potential renal transplantation. Diabetes, hypertension and glomerulonephritis are 
the most common underlying causes of CKD which lead to renal failure with incidence rates 
of 153, 99, and 23.7 cases per million people respectively19. However, the majority of 
patients with CKD will never reach ESRD outcompeted instead by the risk of death which 
may result from cardiovascular complications. For patients with stage G3 CKD the proportion 
who reach renal failure is low as demonstrated by incidence rates of 1.3-2% after five 
years20,21. This increases to 4% after ten years20 but may be higher as one study published a 
figure of 34.6% in a non-Caucasian population22. 
Risk factors associated with the development of renal failure include being of non-white 
ethnicity and the underlying cause for CKD. We have known for a long time that prevalence 
of ESRD is higher in non-white populations23, in spite of reduced prevalence rates for CKD 
itself. This higher incidence of progression is thought to be attributed to an increased 
prevalence of risk factors such as type 2 diabetes in South Asians and hypertension in Afro-
Caribbeans; as well as a greater prevalence of diseases which are of higher risk of 
progression e.g. chronic interstitial nephritis and focal glomerulosclerosis. However, 
compared to Caucasians there is a relative lack of knowledge with regards to the prevalence 
of early stage CKD in non-white ethnic groups. 
The lifestyle factors obesity, physical inactivity and smoking have also been linked to an 
increased risk of developing ESRD18. Patients with self-reported low levels of physical activity 
are twice as likely to develop ESRD or die from CKD-related causes. In the same cross-
sectional study, morbid obesity was shown to have a similar albeit weaker relationship 
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which was at least partly influenced by the presence of the co-morbidities diabetes and 
hypertension. However, although these associations exist following adjustment for many 
confounding factors, we cannot disregard the fact that CKD itself can reduce a person’s 
physical activity and that these risk factors are also directly linked with cardiovascular risk. 
There is evidence to support smoking cigarettes as a risk factor for developing CKD in both 
diabetic and non-diabetic patients16–18. The number of cigarettes smoked potentially exhibits 
a dose-response relationship with risk of ESRD and CKD-related death whereby the 
increasing number of cigarettes smoked per day increased the combined risk18. However, 
this association did not persist in separate analysis focusing on ESRD which supports the 
theory that smokers are less likely to reach ESRD and instead die of cardiovascular 
complications to which smoking is a major risk factor. 
Worldwide, there are 2 million patients in receipt of treatment for ESRD of which more than 
80% are treated in more affluent countries including the USA, Japan, Germany, Brazil and 
Italy24. This pattern is likely to be explained by having ageing populations with high 
prevalences of hypertension and diabetes alongside unrestricted access to well-structured 
healthcare systems. Projections based on the increasing ageing populations in both India and 
China predicts a disproportionate rise in the incidence of ESRD3. Overall, this would lead to a 
greater number of deaths due to the lack of treatment resources and facilities for ESRD; an 
issue currently problematic for lower and middle income countries worldwide24. 
 
1.4 Global Burden of CKD and its Complications 
In 2010 the Global Burden of Disease Study ranked CKD 18th in the list of causes of total 
number of global deaths; a position rise of 9 places from its 27th position ranking in 1990. 
The age-standardised annual death rate increased from 15.7 per 100,000 to 16.3 per 
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100,000 over the 2 decade period; an 82% increase in years of life lost due to premature 
death25. In CKD, the most common causes of mortality are due to cardiovascular events such 
as myocardial infarction or stroke but CKD itself has many complications beyond those of a 
cardiovascular nature. These include but are not limited to anaemia, electrolyte imbalances 
and acid-base disturbance; all of which contribute to the overall costs of CKD and its 
complications which was estimated to be between £1.44 to £1.45 billion pounds in 2009-
2010 (approximately 1.3% of the NHS total budget)26. 
 
1.4.1 Vascular Risk 
It was first pointed out in 1974 by Lindner et al.27 that CKD patients suffer from an increased 
risk of cardiovascular morbidity and mortality through the accelerated development of 
atherosclerosis, a disease process whereby vascular damage is caused by cholesterol and fat 
deposition within the walls thereby narrowing the arteries throughout the body. The 
potential cardiovascular complications from this process include ischaemic heart disease, 
myocardial infarction (MI), stroke, and peripheral vascular disease. CKD patients may also 
suffer from arteriosclerosis followed by the possible development of structural heart 
abnormalities which may culminate in heart failure28 which is in fact the most common 
cardiovascular complication in CKD patients29. Vascular disease itself is also a risk factor for 
CKD progression, a relationship that will be explored further in section 2.1.3. 
In recent years it has become widely accepted that CKD itself is an independent risk factor 
for cardiovascular disease, an association often explained by the presence of several 
“traditional” and/or “non-traditional” risk factors. “Traditional” risk factors are those which 
are linked to CVD in “normal” patients and include older age, diabetes, hypertension and 
dyslipidaemia. “Non-traditional” risk factors are more specific to CKD patients. Examples 
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include volume overload, metabolic abnormalities, albuminuria and anaemia to name a 
few28.  
There is substantial evidence showing that the prevalence of CVD in CKD patients is directly 
correlated with the CKD severity and exhibits a dose-response relationship in this regard. 
Evidence from meta-analysis also shows that once GFR declines below 60 ml/min/1.73 m2, 
the risk of death due to cardiovascular causes increases exponentially30, a pattern that has 
also been observed independently with regards to stroke risk31. In patients receiving renal 
replacement therapy, mortality rates are 10-20 times higher than those without CKD 
following adjustment by gender and age32. Unsurprisingly, having a prior history of 
cardiovascular event puts patients at high risk of subsequent mortality when compared to 
patients with no previous history33. 
The development of heart failure is common in the pathogenesis of CKD and the prevalence 
is as high as 40% in CKD patients34. Compared to people with normal levels of renal function, 
adults with CKD (eGFR less than 60 ml/min/1.73 m2) are at three times greater risk of 
developing heart failure35. This association is particularly pertinent for those starting renal 
replacement therapy, as the presence of heart failure at this stage is an independent 
predictor of increased mortality in both the short36 and long term37,38. In fact overall, the 
three year survival rate of patients with ESRD who are diagnosed with heart failure is as low 
as 13% from the date of diagnosis39. 
 
1.4.2 Anaemia 
Interstitial cells within the kidneys are responsible for the synthesis of erythropoietin, a 
hormone which acts within red bone marrow to stimulate the proliferation of red blood 
cells. With increasing CKD severity, synthesis of this hormone is reduced which typically 
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causes anaemia of a normochromic, normocytic variety. This anaemia is also seen in other 
chronic diseases but in CKD concurrent iron deficiency is common due to either bleeding or 
poor dietary intake which, alongside the “functional iron deficiency” state caused by 
inhibition of iron release from the liver, may cause a hypochromic, microcytic picture 
instead. 
Anaemia itself may be quantitatively 
defined as a haemoglobin level below a 
certain threshold depending on the cut-
offs used (see Box 1). Thus estimated 
total prevalence rates are highly variable 
depending on the clinical definition 
ranging from 2.9% using the NICE 
definition to 13.8% with the KDIGO 
definition within the same study40. 
However, regardless of the definitions used, as GFR declines so do haemoglobin levels 
leading to increasing prevalence of anaemia with increasing CKD stage in both diabetic and 
non-diabetic CKD patients41. Figures from the NHANES III study show that prevalence is two-
fold greater in people with CKD compared to those without: 15.4% prevalence to 7.6% 
respectively41. The risk of developing anaemia is also greater for those with diabetes, 
demonstrated by the prevalence of diabetes being almost two times greater in patients with 
low haemoglobin compared to those with normal levels42. In ESRD, 68% of patients are 
anaemic43 which not only reduces quality of life44 but also increases incidence rates of heart 
failure37 and myocardial infarction45. If left untreated, anaemia can have dire consequences 
for all CKD patients and has been associated with higher rates of hospitalisation and 
mortality following both renal and cardiovascular events46,47. 
Anaemia Definitions 
KDIGO1: 
 men and postmenopausal women <13g/dl 
 premenopausal women <12 g/dl 
K/DOQI81: 
 men and postmenopausal women <12 g/dl 
 premenopausal women <11 g/dl 
Other / NICE2: 
 Hb <11 g/dl 




1.4.3 Metabolic Acidosis and Metabolic Bone Disease 
In CKD, as renal function declines and nephron loss increases, the tight control and 
regulation of acid-base balance can go awry. Normally, homeostasis of acid-base balance 
involves 3 main processes: intra and extracellular buffering, alveolar ventilation, and renal 
excretion of hydrogen (H+) ions. In CKD, it is the latter of these processes which when 
impaired leads to the retention of H+ and therefore metabolic acidosis. The underlying 
mechanism for this impairment is mostly due to an overall reduction in urinary ammonia 
production which acts as a buffer for H+ by combining with it to form ammonium which can 
then be excreted; although less commonly patients with CKD may also suffer from the 
urinary loss of bicarbonate ions48. In chronic metabolic acidosis, the reabsorption of bone 
releases base to buffer the excess of acid by releasing calcium, phosphate and carbonate 
which can later lead to osteopoenia and renal osteodystrophy49. Besides metabolic bone 
disease, chronic acidosis may also lead to a number of other deleterious consequences 
including muscle catabolism, systemic inflammation and reduced albumin synthesis 50–52 to 
name but a few. 
Metabolic acidosis has been shown to increase the risk of progression in non-dialysis 
dependent patients with CKD53. Evidence comes from several observational studies which 
have demonstrated an association between reduced serum bicarbonate levels and adverse 
renal events, defined as progression to ESRD, eGFR decline of 50% or a predefined reduction 
in eGFR compared to baseline values depending on the study53–55. Low serum bicarbonate 
levels are also significantly associated with increased mortality rates in both non-dialysis 
dependent54,56,57 and dialysis dependent patients58. Evidence from the Modification of Diet in 
Renal Disease (MDRD) study also shows an increased risk of renal failure for patients with 




1.4.4 Volume Overload 
Fluid overload is a common complication for patients especially in the later stages of chronic 
kidney disease and is closely linked to disturbances of sodium balance. There are two 
underlying mechanisms which may predispose a patient to fluid overload: either a reduction 
in the kidney’s ability to concentrate or dilute urine or the abnormal handling of solutes 
leading to the retention of water. With regards to the former mechanism, the dysregulation 
of water balance can occur independently of sodium concentration. In normal renal 
function, urine concentration is controlled by the secretion of anti-diuretic hormone 
released from the posterior pituitary which promotes the retention of water by increasing its 
reabsorption in the collecting ducts. Normal production of this hormone is unchanged in 
CKD but as renal function deteriorates the kidneys become less able to dilute or concentrate 
urine which eventually leads to the development of isothenuria, whereby urine osmolality 
becomes equal to that of protein-free plasma. At any stage of CKD, if intake of water 
exceeds the ability of the kidneys to excrete it, then fluid overload may occur and can lead to 
the development of further complications such as peripheral oedema, pulmonary oedema 
and congestive heart failure. Overload due to poor excretion of sodium does not normally 
become an issue until GFR deteriorates beyond the threshold of 25 ml/min/1.75 m2 59. 
There is extensive evidence which illustrates the associated risk of mortality with fluid 
overload in patients receiving dialysis60,61 likely resulting from the development of 
cardiorenal syndrome in which fluid overload causes hypertension, puts extra strain on the 
heart and predisposes to heart failure later on62. The association of increased mortality is 
also present in late-stage predialysis patients in terms of both all-cause and cardiovascular 
mortality63. However, although it is accepted that fluid overload develops early on in CKD, 




1.4.5 Electrolyte Disturbances 
The dysfunction of homeostatic mechanisms which control electrolyte balance may lead to 
abnormalities in serum sodium and potassium levels. Most commonly this is due to impaired 
water homeostasis which can cause both high (hypernatraemia) and low sodium levels 
(hyponatraemia), although hypernatraemia is a lot less common and only tends to happen 
when fluid intake is reduced alongside intercurrent illness. Normally compensatory 
mechanisms which are external to the renal system are able to maintain the balance of 
electrolytes in the face of deteriorating renal function so imbalances are not common until 
the later stages of CKD (GFR < 10-25 ml/min/1.73 m2)64.  
Hyponatraemia is typically caused by the dilutional effect of fluid overload, the mechanisms 
of which have been mentioned above, but may also be a side effect of diuretic use especially 
thiazide diuretics. A low serum sodium level is an independent predictor of increased 
mortality and increased length of hospital admission in hospitalised patients without CKD65 
but evidence from CKD patients is limited. Waikar et al.66 demonstrated a significant 
association between lower serum sodium levels and increased risk of all-cause death in CKD 
patients receiving haemodialysis, although this was not significant when analysis was 
restricted to cardiovascular mortality only. Hyponatraemia also increases the risk of 
infection leading to hospitalisation in haemodialysis patients67 but there is little to no 
evidence exploring hypernatraemia in dialysis patients.  Despite this, in non-dialysis patients 
serum sodium levels have been shown to exhibit a U-shaped relationship with mortality 
which means that high sodium levels are also harmful68. 
With regards to potassium homeostasis, hyperkalaemia may result from reduced potassium 
excretion which decreases proportionately to GFR decline, although extra-renal 
compensatory mechanisms may be able to maintain potassium homeostasis at eGFR levels 
as low as 10 ml/min/1.73 m2 59. Hyperkalaemia itself is a potentially life-threatening medical 
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condition that can cause dangerous cardiac arrhythmias that may lead to death in both CKD 
non-CKD patients. In CKD patients, hyperkalaemia is most commonly caused by interference 
in the renin-angiotensin-aldosterone system, often as a side-effect of medical intervention 
to reduce risk of progression with the use of blood pressure (BP) controlling drugs such as 
ACE inhibitors, angiotensin receptor blockers and potassium-sparing diuretics or aldosterone 
antagonists69,70, but my also result from potassium shift into the extracellular space resulting 
from metabolic acidosis71. As CKD progresses and GFR falls, the odds of developing 
hyperkalaemia increase alongside an increasing odds of mortality72. It is associated with an 
increased risk of death in hospitalised patients and has also been shown to be significantly 
more prevalent in patients with CKD than the general population: prevalence up to 40-50% 
compared to 2-3% respectively73. 
 
1.4.6 Vitamin D and Secondary Hyperparathyroidism 
The kidneys play an important role in vitamin metabolism; converting 25(OH)D into its active 
form 1,25(OH)2D . In turn, 1,25(OH)2D helps to regulate bone metabolism through its effects 
to promote an increase in serum calcium by the stimulation of bone osteoclastic activity,  
absorption in the small intestine, reabsorption in the distal convoluted tubules of the 
kidneys and suppression of the parathyroid glands74. In chronic kidney disease, the 
pathological development of secondary hyperparathyroidism results from elevated 
fibroblast growth factor 23 (FGF-23) which leads to a reduction in 1,25(OH)2D and thus 
reduction in serum calcium levels. Low circulating serum calcium then promotes the 
synthesis and secretion of parathyroid hormone which can culminate in the development of 
secondary hyperparathyroidism75. As with all previously mentioned complications of CKD, 
the prevalence of secondary hyperparathyroidism increases with declining renal function as 
can be shown by a prevalence of 40-80% for patients with stages 3-4 which increases to 95% 
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for those with stage 574. High serum calcium and phosphorous levels due to secondary 
hyperparathyroidism are also associated with vascular calcification which itself causes 
increased morbidity and mortality. It is, however, worth noting that high levels of 
parathyroid hormone are often present in the absence of abnormal calcium and/or 
phosphate levels and can be detected in the early stages of CKD: 12% of patients with eGFR 
greater than 80 ml/min/1.73 m2 and 56% of those with eGFR less than 60 ml/min/1.73 m2 76. 
 
1.5 Evolution of Relevant CKD Guidelines 
It is widely accepted within the renal specialist community that recommendations made by 
NICE guidelines are not based on particularly strong evidence. The following section aims to 
investigate the relevant guidelines and the evidence underpinning them by exploring their 
evolution from 2008 to 2014; focusing on the management and interventions aimed to assist 
in the amelioration of progressive decline in renal function and its consequences (e.g. bone 
metabolism problems). 
 
1.5.1 Who should be tested? 
Guidelines 1.1.27-1.1.29 focus on which patients should be candidates for CKD testing. 
Recommendations amended from 2008 promote regular testing for at risk patients using 
known nephrotoxic medications such as lithium, non-steroidal anti-inflammatory drugs 
(NSAIDs), cyclosporin or tacrolimus, although no evidence was reviewed to underpin this 
guideline instead relying on advice from the British National Formulary to provide guidance 
on the frequency of testing2. Following a review of the evidence on potential risk factors for 
progression, a new guideline 1.1.28 (see Box 2 below) was added in 2014 and lists the risk 
factors, the presence of which would support testing for CKD. The evidence reviewed was 
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 acute kidney injury (see recommendation 1.3.9) 
 cardiovascular disease (ischaemic heart disease, chronic heart failure, peripheral vascular 
disease or cerebral vascular disease) 
 structural renal tract disease, recurrent renal calculi or prostatic hypertrophy 
 multisystem diseases with potential kidney involvement – for example, systemic lupus 
erythematosus 
 family history of end-stage kidney disease (GFR category G5) or hereditary kidney disease 
 opportunistic detection of haematuria [new 2014] 
1.1.29 Do not use age, gender or ethnicity as risk markers to test people for CKD. In the absence of 
metabolic syndrome, diabetes or hypertension, do not use obesity alone as a risk marker to test people 
for CKD. [2008, amended 2014] 
 
Box 2: NICE Guidelines on who should be offered CKD testing from CG182 
based mostly on several large-scale cross-sectional studies and a few cohort studies but no 
randomised controlled trials (RCT)2. Cross-sectional studies of note include the American 
NHANES III77, Australian Ausdiab study11 and a large Norwegian study10 using data from the 
HUNT II study78. Guideline 1.1.29 (see Box 2) was amended to outline risk factors for which 
evidence supporting progression was deemed to not be strong enough to recommend 
testing e.g. gender, ethnicity and obesity (without metabolic syndrome)2. However, whilst 
conclusions regarding gender10,11,77, ethnicity17,77 and obesity18,79 were inconsistent between 
studies, the studies reviewed to examine the relationship between age and CKD all support 
increasing age as a risk factor10,11,77. In fact, there is evidence which shows 93% of CKD stages 
3-5 can be identified from screening people either greater than 55 years old, hypertensive or 
diabetic80. The recommendation to include age in guideline 1.1.29 instead of 1.1.28 is 





As previously mentioned NICE currently recommends the use of a 5 stage classification 
system which was initially conceived in 2002 by the National Kidney Foundation Kidney 
Disease Outcomes Quality Initiative (K/DOQI)2,81. The subdivision of stage 3 into 3a (GFR 45-
59 ml/min/1.73m2) and 3b (30-44 ml/min/1.73m2) was a change first suggested by NICE in 
2008 and later incorporated into the KDIGO guidelines in 20121,2. With evidence supporting 
proteinuria as an important risk factor for CKD progression, 2008 NICE guidelines also 
recommended the use of the suffix ‘P’ to signify significant proteinuria at any stage, defined 
as ACR >30 mg/mmol or PCR > 50 mg/mmol, but this has since been superseded by the ACR 
categories of staging recommended in the 2012 KDIGO report and later adopted by NICE in 
20141,2. This followed increasing evidence for the now widely accepted view that 
albuminuria increases the risk of CKD progression independently of eGFR values. 
 
1.5.3 Frequency of Monitoring 
Defining progression of CKD has previously been considered a difficult problem to address, 
due in part to the subsequently refuted belief that CKD as a disease always followed a linear 
progression pattern. It is now more widely accepted that having CKD is not inherently 
associated with further deterioration in renal function, that many patients will not develop 
end-stage renal disease and that those that do often follow a non-linear trajectory. This only 
makes the task of identifying patients at greater risk of adverse outcomes more arduous. 
Prior to 2014, the NICE guidance on the suggested frequency of monitoring kidney function 
in CKD was based solely on the opinions of those within the guideline development group 
(GDG); not on evidence (see table 3).  
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Table 3: Table showing the suggested frequency of monitoring according to CG73 (2008) 
Measurement of eGFR: how often? 
Annually in all at-risk groups. 
During intercurrent illness and peri-operatively in all patients with CKD. 
Exact frequency should depend on the clinical situation. The frequency of testing may be reduced 
where eGFR levels remain very stable but will need to be increased if there is rapid progression. 
Stage eGFR range (ml/min/1.73m
2
) Typical testing frequency 
1 and 2 ≥60 + other evidence of kidney 
disease 
12 monthly 
3a and 3b 30-59 6 monthly 
4 15-29 3 monthly 
5 <15 6 weekly 
 
In 2014, NICE reviewed 11 retrospective cohort studies looking into progression and 
mortality rates for CKD and various risk factors which showed associations between 
progressive decline in eGFR or increasing ACR and increased mortality or risk of progression 
to ESRD82–87. This was incorporated into current 2014 guidelines (guideline 1.3) so ACR is 
now a risk factor for which more frequent monitoring is recommended as well as 
deteriorating GFR (see Figure 1). The guideline also advises that monitoring should also be 
determined on an individual basis according to underlying cause of CKD, comorbidities, 
intercurrent illness and their agreed upon management/treatment plan. However, further 




Figure 1: Table Showing the Suggested Annual Frequency of Monitoring GFR (by GFR and ACR Category) for 
People with CKD (NICE Guidelines adapted from KDIGO) 
 
1.5.4 Defining Progression 
Evidence reviewed in 2014 led to an update on the definition of accelerated progression 
which previously defined progression based on an absolute drop in eGFR by either 5 
ml/min/1.73 m2 within a twelve month period or 10 ml/min/1.73 m2 within a five year 
period. It now supports the updated recommendations that define progression as either an 
absolute drop of 15 ml/min/1.73 m2 in 1 year or a ‘sustained decrease in GFR of 25% or 
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more and a change in GFR category within 12 months’ as both were associated with greater 
mortality risk82 and the latter an up to five-fold increased risk of progression to ESRD83.  
Although several cohort studies reviewed can support the notion that risk of ESRD disease 
increases with decreasing eGFR83,85–87, the suggested 25% decrease in GFR is solely based on 
a single retrospective large-scale cohort study83 as other studies could not provide a 
quantitative threshold at which one would be at a significantly increased risk of adverse 
outcomes and therefore form the basis on which to define progression. 
Otherwise, the guidelines relating to the identification of progression remain largely 
unchanged as evidence underpinning them has not been reviewed since 2008. Both the 
original and current guidelines recommend using at least three GFR measurements over a 
period greater than three months in order to identify progression as well as repeating GFR 
measurements within two weeks of newly reduced GFR findings in order to exclude acute 
causes for deterioration. The current 2014 guideline (1.3.4) is an amalgamation of two prior 
2008 recommendations whereby examples given for these causes of acute deterioration 
have also been reworded: ‘acute kidney injury or initiation of ACE inhibitor/ARB therapy’ has 
been replaced by ‘acute kidney injury or starting renin–angiotensin system antagonist 
therapy.’ The 2014 GDG accepted that the trajectory of an individual’s GFR decline is 
potentially non-linear and aimed to ‘highlight intervention strategies that can be chosen 
based on current rate of decline to slow progression’ by adding ‘and take this into account 
when planning intervention strategies’ to the recommendation (1.3.6) which otherwise 





1.5.5 Risk Factors 
Guideline 1.3.7 (see Box 4) lists the risk factors for potential CKD progression and advises 
that patients with them should have their health optimised. Further guidance on how to do 
this is not directly addressed with the exception of chronic NSAID use for which additional 
advice is provided in guideline 1.3.8, a recommendation leftover from 2008. The addition of 
guideline 1.3.7 in 2014 followed a review of evidence on CKD and ethnicity, obesity, 
smoking, cardiovascular disease, acute kidney injury, urinary tract obstruction or chronic 
NSAID use but not hypertension, diabetes mellitus or proteinuria as these were already well-
established risk factors for progression. Evidence from a single pooled analysis of the 
prospective longitudinal cohort studies (Atherosclerosis Risk in Communities and 
Cardiovascular Health Study) provided good evidence to support the inclusion of CVD as an 
independent risk factor for renal function deterioration88. Current 2014 guidance includes 
1.3.3 Define accelerated progression of CKD as: 
 a sustained decrease in GFR of 25% or more and a change in GFR category within 
12 months or 
 a sustained decrease in GFR of 15 ml/min/1.73 m2 per year. [new 2014] 
1.3.4 Take the following steps to identify the rate of progression of CKD: 
 Obtain a minimum of 3 GFR estimations over a period of not less than 90 days. 
 In people with a new finding of reduced GFR, repeat the GFR within 2 weeks to exclude 
causes of acute deterioration of GFR – for example, acute kidney injury or starting renin–
angiotensin system antagonist therapy. [2008, amended 2014] 
1.3.5 Be aware that people with CKD are at increased risk of progression to end-stage kidney 
disease if they have either of the following: 
 a sustained decrease in GFR of 25% or more over 12 months or 
 a sustained decrease in GFR of 15 ml/min/1.73 m2 or more over 12 months. [2008, 
amended 2014] 
1.3.6 When assessing CKD progression, extrapolate the current rate of decline of GFR and take 
this into account when planning intervention strategies, particularly if it suggests that the person 
might need renal replacement therapy in their lifetime. [2008, amended 2014] 
 
Box 3: NICE guidelines on CKD Progression from CG182 
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both smoking and ethnicity in spite of the cohort and case-control studies reviewed being 
deemed as ‘not conclusive’ by the GDG. Obesity was also omitted as a risk factor because 
the single case-series reviewed yielded no significant results89. Furthermore, the inclusion of 
urinary outflow obstruction within the current guidelines was completely unsupported by a 
non-existent evidence base at that time. Zero studies were reviewed which meant that its 
inclusion was based instead on the clinical judgement of the GDG from which consensus 
agreed that untreated outflow obstruction could cause CKD. 
 
1.5.6 Blood Pressure Control  
Despite good evidence supporting blood pressure control as an intervention to ameliorate 
the risk of progression and risk of cardiovascular events, the optimal target range for 
patients with CKD remains poorly defined by the international community as shown by the 
lack of consensus between guidelines. 2002 K/DOQI guidelines81 advise maintaining blood 
pressure below 130/80 mmHg whereas 2008 SIGN guidelines90 only focus on a systolic target 
1.3.7 Work with people who have any of the following risk factors for CKD progression to optimise 
their health: 
 cardiovascular disease 
 proteinuria 




 African, African-Caribbean or Asian family origin 
 chronic use of NSAIDs 
 untreated urinary outflow tract obstruction. [new 2014] 
 
1.3.8 In people with CKD the chronic use of NSAIDs may be associated with progression and 
acute use is associated with a reversible decrease in GFR. Exercise caution when treating people 
with CKD with NSAIDs over prolonged periods of time. Monitor the effects on GFR, particularly in 
people with a low baseline GFR and/or in the presence of other risks for progression. [2008] 
 
Box 4: NICE guidelines on risk factors for CKD progression from CG182 
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of <130 mmHg if proteinuric (1g/day) and the more recent 2012 KDIGO guidelines1 
recommend a target of <140/90 mmHg. Currently the NICE guidelines2 on blood pressure 
targets recommend a systolic target range of 120-139 mmHg and a diastolic target <90 
mmHg for patients with CKD but a lower target of 120-129/80 mmHg is advised for patients 
with diabetes or ACR ≥ 70 mg/mmol. However, as no review of the evidence was conducted 
in 2014, these guidelines remain unchanged from 2008 and are therefore supported by 
literature at least 8 years old91. 
With regards to the pharmacological management options for controlling blood pressure, an 
extensive review of studies on antihypertensive therapy use in CKD patients was conducted 
in order to determine which drugs were the most cost-effective and clinically suitable 
options to recommend.91 This led to the addition of guidelines 1.6.3, 1.6.4 and 1.6.5 
alongside an amendment to guideline 1.6.8 in 2014 (see Box 5) which promote renin-
angiotensin system (RAS) inhibition through the use of low-cost angiotensin-converting 
enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB) or direct renin inhibitors for 
people with CKD and the following caveats: 
 diabetes mellitus with an ACR ≥ 3mg/mmol 
 hypertension with and ACR ≥30 mg/mmol 




Combinations of RAS inhibitors are not recommended by NICE guideline 1.6.4 which is 
supported by RCTs which reported either no significant benefit or adverse effects of 
combined ACE inhibitor and ARB therapy compared to ACE inhibitor or ARB therapy alone92–
94. Otherwise guideline 1.6.5 recommends that patients should follow the standard NICE 
guidelines for hypertension outlined in NICE guideline CG12795 i.e. commence an ACE 
inhibitor or calcium channel blocker first-line depending on age and ethnicity. The 
amendment to guideline 1.6.8 acknowledges the risk of hyperkalaemia in CKD often as a side 
effect of RAS inhibitors by not recommending the commencement of them in patients who 
have serum potassium greater than 5.0 mmol/l. However it was also stated that ‘there was 





Choice of antihypertensive agent 
1.6.3 Offer a low-cost renin–angiotensin system antagonist to people with CKD and: 
 diabetes and an ACR of 3 mg/mmol or more (ACR category A2 or A3) 
 hypertension and an ACR of 30 mg/mmol or more (ACR category A3) 
 an ACR of 70 mg/mmol or more (irrespective of hypertension or cardiovascular 
disease)
[4]
. [new 2014] 
 
1.6.4 Do not offer a combination of renin–angiotensin system antagonists to people with CKD. [new 
2014] 
 
1.6.5 Follow the treatment recommendations in Hypertension (NICE guideline CG127) for people with 
CKD, hypertension and an ACR of less than 30 mg/mmol (ACR categories A1 and A2), if they do not 
have diabetes. [new 2014] 
 
1.6.8 Do not routinely offer a renin–angiotensin system antagonist to people with CKD if their 
pretreatment serum potassium concentration is greater than 5.0 mmol/litre. [2008, amended 2014] 
Box 5: NICE guidelines on antihypertensive therapy from CG182 
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1.5.7 Reducing Cardiovascular Risk 
Advice on the amelioration of cardiovascular risk through statin therapy is no longer 
included within the NICE CKD guideline (CG182)2 but has instead been incorporated into a 
separate section within the recommendations on lipid modification (CG181)96 as of 2014. 
Guideline 1.3.27 from this advises offering  a starting dose of 20 mg of atorvastatin to reduce 
cardiovascular risk in patients with CKD; dose to be increased if a minimum 40% reduction in 
non-high density lipoprotein (HDL) cholesterol is not observed with a given GFR ≥ 30 
ml/min/1.73m2. Specialist advice should be sought when considering augmenting the dose 
of atorvastatin for patients within CKD GFR categories G4 and G5. Statin intolerance also 
welcomes specialist advice as statins are the only lipid-lowering drug recommended within 
the guideline96, although there were no trials comparing statins and other lipid-lowering 
therapies97. Overall, these recommendations are underpinned by poor quality (level 1) 
evidence from three meta-analyses98–100, two of which had significant heterogeneity99,100. 
With regards to slowing progression and proteinuria reduction no consensus was found 
between these studies but the largest study did find a significant reduction in cardiovascular 
risk100 which therefore forms the basis for the recommendation of statin therapy in CKD. 
CKD patients are known to be at high risk of cardiovascular and cerebrovascular events and 
are shown to be more likely to suffer from atrial fibrillation (AF)101. Anti-platelet or 
anticoagulant therapy is normally used to reduce cardiovascular risk but in CKD patients this 
has its own risks as increasing CKD severity is associated with increasing risk of bleeding and 
Warfarin use has been linked to CKD progression. NICE attempted to answer the question of 
‘For people with CKD, what is the clinical and cost effectiveness of oral antiplatelet and 
anticoagulant therapy in reducing cardiovascular disease?’ by reviewing the evidence in 
201491. Unfortunately there were no RCTs found which directly addressed this question as, 
although there were trials which explored the use of anti-platelet and anticoagulant therapy, 
none had been specifically designed to explore the relationship in CKD patients. Trials 
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reviewed therefore included CKD patients as a subgroup and most as a post-hoc analysis. 
Following this review of newer poor quality evidence, the original recommendation to offer 
anti-platelets remains unchanged from 2008 but now acknowledges the increased risk of all 
bleeding, not just minor (see Box 6). Apixiban may also be considered instead of warfarin in 
patients with eGFR 30-50 ml/min/1.73 m2 with AF but this based on findings from a single 
study102 which then supported the incorporation of guideline TA275103 into CG1822 as 
evidence was based on the same trial population. 
 
1.5.8 Bone Metabolism, Osteoporosis and CKD-MBD 
Guidelines 1.7.1, 1.7.2 and 1.7.3 pertain to the identification and treatment of osteoporosis 
in CKD patients but have not had their evidence reviewed, and therefore have not been 
updated, since 2008. They are underpinned by cross-sectional study evidence only which 
show that calcium levels decrease and phosphate levels increase in advanced CKD76,104. 
However, despite the statistical significance of these findings, they were deemed not to be 
clinically significant by the GDG. The guidelines reflect this by not recommending 
investigation of patients until eGFR drops below 30 ml/min/1.73 m2; although treatment 
Oral antiplatelets and anticoagulants 
1.6.16 Offer antiplatelet drugs to people with CKD for the secondary prevention of cardiovascular 
disease, but be aware of the increased risk of bleeding. [new 2014] 
1.6.17 Consider apixaban in preference to warfarin in people with a confirmed eGFR of 30–
50 ml/min/1.73 m
2
and non-valvular atrial fibrillation who have 1 or more of the following risk factors: 
 prior stroke or transient ischaemic attack 
 age 75 years or older 
 hypertension 
 diabetes mellitus 
 symptomatic heart failure. [new 2014] 
 
Box 6: NICE guidelines on antiplatelet and anticoagulant use from CG182 
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with bisphosphonates is recommended if osteoporosis is diagnosed at any GFR stage (see 
Box 7)91. 
 
In depth advice on managing CKD-MBD is stated to be ‘beyond the scope’ of NICE guidelines 
so doctors are advised to ‘seek advice from your local renal service’ if unsure about what to 
do91. Guidelines 1.7.4 to 1.7.7 were added in 2014, relate to vitamin D supplementation and 
are based on low-moderate quality RCT evidence from a review of 8 small trials conducted 
between 1988 and 201191,105–108. Using vitamin D supplementation as primary prevention of 
CKD-MBD is not recommended by the guidelines as evidence didn’t support clinical benefit 
in the absence of vitamin D deficiency. Also despite inactivated vitamin D being most 
commonly prescribed in the UK, there were no trials reviewed using inactive vitamin D and 
trials on activated forms showed inconclusive results and were associated with causing 
hypercalcaemia91,105–108. However, despite this, active vitamin D is recommended for 
persistent CKD-MBD symptoms in patients with GFR < 30 ml/min/1.73 m2 as the GDG 
attributed more weight to the physiological impairment to vitamin D activation which occurs 
with worsening renal function. Guideline 1.7.7 does however acknowledge this risk by 
recommending monitoring of calcium and phosphate levels in patients receiving alfacalcidol 
or calcitriol.91 
Bone metabolism and osteoporosis 
1.7.1 Do not routinely measure calcium, phosphate, parathyroid hormone (PTH) and vitamin D levels 
in people with a GFR of 30 ml/min/1.73 m
2
 or more (GFR category G1, G2 or G3). [2008] 
1.7.2 Measure serum calcium, phosphate and PTH concentrations in people with a GFR of less than 
30 ml/min/1.73 m
2
 (GFR category G4 or G5). Determine the subsequent frequency of testing by the 
measured values and the clinical circumstances. Where doubt exists, seek specialist opinion. [2008] 
1.7.3 Offer bisphosphonates if indicated for the prevention and treatment of osteoporosis in people 
with a GFR of 30 ml/min/1.73 m
2
 or more (GFR category G1, G2 or G3). [2008] 
 




Guideline 1.7.8 within CG1822 recommends testing haemoglobin in patients with eGFR 
below 45 ml/min/1.73m2 in order identify anaemia; defined as a haemoglobin level < 110 
g/L. It also signposts doctors to separate guidelines on anaemia management in CKD 
(NG8)109 which despite being published in June 2015, much of the evidence has not been 
reviewed since 2011 or even 2006. According to NG8109, CKD should be investigated and 
managed if patients are either symptomatic or have a measured haemoglobin result < 110 
g/L. It makes no statement regarding a threshold of eGFR below which testing for anaemia 
should be carried out unlike guideline 1.7.8 in CG1822 but instead suggests that anaemia of 
CKD should be suspected and investigated in anaemic patients with eGFR < 60 ml/min/1.73 
m2. The threshold of 45 ml/min/1.73 m2 is based on results from a single large UK cross-
sectional study which shows a sharp rise in anaemia prevalence from stage G3b onwards40. It 
was published in 2007 so will not have been considered in the formulation of NG8; whose 
guideline on the diagnostic role of GFR has not been reviewed since 2006109. 
Evidence on determining iron status in CKD patients and starting iron therapy was reviewed 
in 2015 leading to the creation of new guidelines on testing and management110. Of eleven 
studies reviewed, only two were RCTs111,112 with the remaining nine being diagnostic 
accuracy reviews. Guidelines 1.1.3 and 1.1.4 from NG8 recommend using the percentage of 
hypochromic red blood cells, not transferrin or ferritin levels, to assess iron status; with a 
level > 6% being suggestive of iron deficiency109. However the generalisability of the 
evidence underpinning these guidelines is questionable as 10/11 studies were conducted on 
patients with ESRD110. The guidelines on haemoglobin target ranges were last reviewed in 
2011 and are unclear regarding what to aim for when treating anaemia of CKD in patients 
not being treated with erythropoietic stimulating agents (ESAs). It states that ‘patient 
preferences’, ‘symptoms and comorbidities’ and ‘the required treatment’ are all factors that 
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should be considered when determining the optimal haemoglobin levels but provides no 
suggested levels so one may assume correction is to within normal limits109. 
Additional guidance on managing anaemia with ESAs and blood transfusions is also found 
within NG8 but will not be discussed here as these are not commonly used to manage 
patients with stage G3 CKD, the primary focus of our study. 
 
1.5.10 Metabolic Acidosis 
As with the guidelines on CKD-MBD, in depth advise on managing metabolic acidosis is 
stated to be ‘beyond the scope of this guideline’ (guideline 1.7.9)2. The only 
recommendation made by NICE, an addition in 2014, advises considering treating with 
sodium bicarbonate if patients in CKD stages 4-5 have a serum bicarbonate concentration 
less than 20 mmol/L. This is underpinned by poor quality evidence from two RCTs which 
both had inadequate randomisation and allocation concealment113,114. 
 
1.6 Referral Criteria to Secondary Care 
NICE have stated ‘there was no evidence to guide recommendations on who should be 
referred’ which highlights a lack of high quality evidence within the field of renal research 
relating specifically to when to refer CKD patients to secondary care, although admittedly 
this is a difficult question to search for91. In the absence of this evidence, the guidance is 
instead based on ‘the recommendations in other guidelines on who should be referred’ as 
well as ‘the aims and benefits of referral from their own professional standpoint’, with ‘their’ 
referring to members of the NICE Guideline Development Group91.  
NICE guidelines are similar to recommendations outlined in the internationally recognised 
2012 KDIGO report but with a few differences. KDIGO recommends that all CKD patients 
with ACR category 3 (A3) should be referred whereas NICE  guideline 1.5.2 has the added 
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caveat of haematuria alongside category A31,91. In the absence of haematuria, NICE also 
recommends referral at an ACR level greater than 70mg/mmol instead of the 30mg/mmol 
suggested by KDIGO91. The reason for the discrepancy between guidelines is currently 
unexplained especially considering that the evidence underpinning KDIGO referral criteria 
was rated as ‘moderate’ as opposed to the stated ‘no evidence’ supposedly underpinning 
NICE guideline 1.5.1-1.5.51,91. 
The NICE referral criteria are outlined in the box below. 
1.5.1 Take into account the individual's wishes and comorbidities when considering referral. [2008] 
 
1.5.2 People with CKD in the following groups should normally be referred for specialist assessment: 
 GFR less than 30 ml/min/1.73 m2 (GFR category G4 or G5), with or without diabetes 
 ACR 70 mg/mmol or more, unless known to be caused by diabetes and already appropriately 
treated 
 ACR 30 mg/mmol or more (ACR category A3), together with haematuria 
 sustained decrease in GFR of 25% or more, and a change in GFR category or sustained decrease 
in GFR of 15 ml/min/1.73 m
2
 or more within 12 months 
 hypertension that remains poorly controlled despite the use of at least 4 antihypertensive drugs at 
therapeutic doses (see also Hypertension [NICE guideline CG127]) 
 known or suspected rare or genetic causes of CKD 
 suspected renal artery stenosis. [2008, amended 2014] 
1.5.3 Consider discussing management issues with a specialist by letter, email or telephone in cases 
where it may not be necessary for the person with CKD to be seen by the specialist. [2008] 
 
1.5.4 Once a referral has been made and a plan jointly agreed (between the person with CKD or their 
carer and the healthcare professional), it may be possible for routine follow-up to take place at the 
patient's GP surgery rather than in a specialist clinic. If this is the case, criteria for future referral or re-
referral should be specified. [2008] 
 
1.5.5 People with CKD and renal outflow obstruction should normally be referred to urological services, 
unless urgent medical intervention is required – for example, for the treatment of hyperkalaemia, severe 
uraemia, acidosis or fluid overload. [2008] 
 




Chronic kidney disease, a disease with numerous potential complications, is a serious 
medical condition which affects large numbers of people both in the UK and worldwide. 
Despite advances in the understanding and management of CKD and its complications, the 
burden of this disease continues to rise and is predicted to continue alongside projections of 
a worldwide ageing population. The National Institute of Clinical Excellence has formulated 
guidelines aimed to assist UK clinicians manage and reduce progression in patients with this 
condition; but it is accepted that these guidelines are not based on high quality evidence. 
RCTs are considered the gold-standard study design within the field of medical research but 
exploration of the evidence underpinning these guidelines showed a lack of RCT evidence as 
most guidelines are based evidence from lesser study designs such as cohort or cross-
sectional studies. However, this is not surprising as nephrology has a poor RCT publication 
rate115 (see Figure 2). With regards to the referral criteria, it was stated that ‘there was no 
evidence to guide recommendations’ which currently recommend referral at CKD stages G4-
5; not stage G391. As there is no evidence underpinning this recommendation we therefore 










Figure 2: Number of randomized controlled trials (RCT) published in nephrology and 12 
other specialties of internal medicine from 1966 to 2002 (replicated from The Number, 
Quality, and Coverage of Randomized Controlled Trials in Nephrology - Strippoli et al.) 
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CHAPTER 2: CHRONIC KIDNEY DISEASE PROGRESSION 
 
In this chapter we explore the subject of progression in chronic kidney disease by 
investigating the main risk factors associated with CKD progression as well as the 
interventions which have the potential to slow this progression down. We then focus on the 
impact of secondary care referral on progression rates and mortality in order to explore the 
potential benefits which may be provided by secondary care in lieu of primary care. 
 
2.1 Risk Factors for CKD Progression 
2.1.1 Diabetes 
There are several different pathological mechanisms by which diabetes can lead to the 
development of renal damage and therefore chronic kidney disease. Both metabolic and 
haemodynamic changes have already been implicated in causing diabetic nephropathy but 
oxidative stress, endothelial damage and inflammation also play a role in the 
pathophysiology116. The first step in the pathogenesis of diabetic glomerulosclerosis is 
afferent arteriole dilation which leads to an increase in pressure within the glomerulus and 
then glomerular hyperfiltration. Progressive thickening of the basement membrane then 
occurs due to the deposition of extra-cellular matrix in a process known as hyalinosis. 
Mesangial cells expand, protein kinase is activated and subsequent inflammation may cause 
additional secondary damage. The development of glomerular hypertension and its 
subsequent hyperfiltration state increases the permeability of the membrane which allows 
albumin to pass into the urine resulting in microalbuminuria which is recognised as an early 
manifestation of diabetic nephropathy. Diabetes is also a condition known to accelerate the 
development of atherosclerosis which can contribute to the development of renal artery 
stenosis. Reduced blood flow to the kidneys themselves can then cause ischaemia which can 
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result in necrosis of renal tissue, therefore outlining another pathological mechanism by 
which diabetes can cause CKD. 
As previously mentioned, diabetic nephropathy is the leading cause of ESRD which is 
quantified in the SHARP study as relative risk of three when compared to other primary 
causes of renal disease117. Its natural disease progression is associated with the 
development of hypertension and proteinuria, risk factors also independently linked with 
progression of CKD and to be discussed in further detail below. However despite this, the 
increased risk of adverse renal outcomes (ESRD or 40% eGFR reduction) when compared to 
those with hypertensive nephropathy was not found to be significantly associated with 
levels of blood pressure or proteinuria118, therefore supporting diabetes as an independent 
risk factor for progression. Individuals with type 1 diabetes have been shown to naturally 
have highly variable rates of GFR decline without intervention which range from 2-20 
ml/min/year with the overall rate approximated at 12 ml/min/year119,120. Additionally, 
without intervention, 80% of those with type 1 diabetes and microalbuminuria will progress 
to clinical albuminuria within 10-15 years121. Compared to patients without diabetes, there 
is strong evidence which shows that patients with diabetes are more likely to progress to 
end stage renal disease at all GFR stages of CKD and this risk substantially increases once 
eGFR declines below the threshold of 45 ml/min/1.73 m2.122 However, in spite of this, those 
with diabetic nephropathy are still more likely to outcompeted by the risk of mortality and 
die from both cardiovascular and non-cardiovascular causes than reach ESRD122. 
 
2.1.2 Hypertension 
The relationship between hypertension and CKD is complex and bidirectional in nature as 
hypertension is both a cause of CKD and consequence of it. For most patients with essential 
hypertension renal damage starts to occur in the form of benign nephrosclerosis which 
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usually does not affect the glomerulus and instead causes a slow ischaemic nephron loss. 
Autoregulatory dilatation and constriction of the afferent arteriole usually maintains fairly a 
constant pressure within the glomerular capillaries but over time chronic hypertension leads 
to remodelling of these vessels. Should the threshold for the compensatory ability of the 
afferent arteriole be exceeded, then patients may develop a “malignant” nephrosclerosis 
which causes damage to the glomerulus as well as its supplying blood vessels123. Similarly to 
diabetic glomerulosclerosis, this may lead to hyperfiltration, thus causing proteinuria, and 
subsequent hyaline deposition. 
With regards to progression, hypertension is known to independently accelerate the 
progression rate of CKD with observational evidence showing increasing incidence of ESRD 
in CKD patients with blood pressure greater than 130/80 mmHg124–126; as well as evidence 
showing reduced incidence rates of serum creatinine elevation in patients with more 
intensively controlled blood pressure127. As levels of blood pressure increase, patients are 
increasingly more likely to initially develop CKD16 and to then later progress to ESRD which is 
demonstrated by increasing incidence rates at higher stages of hypertension in both men 
and women124; although conversely, systolic blood pressure levels below 110 mmHg have 
also been associated with increased risk of progression in nondiabetic patients 
independently of proteinuria126. Although strong observational evidence associates both 
systolic and diastolic blood pressure levels with the development of ESRD124,125, the 
contribution of raised systolic, as opposed to diastolic, blood pressure is thought to be the 
main contributor to causing renal damage. This is supported by a meta-analysis which 
demonstrated no significant relationship for diastolic BP after accounting for systolic BP126 
and also by another study showing no difference in ESRD rates based on diastolic BP 
targets128. Compared to other causes of primary kidney disease, patients with hypertensive 




2.1.3 Vascular Disease 
We already know that chronic kidney disease increases cardiovascular risk with the majority 
of CKD patients dying from a cardiovascular event as opposed to succumbing to a 
progressive decline in renal function; a trend which is true even in the earlier stages of CKD. 
Prevalence rates of both arterial vascular disease, cardiomyopathy and heart failure are high 
in patients with CKD and are especially high in patients with renal failure34,37,129–131. The 
latter is demonstrated by figures from a Canadian prospective cohort study which showed 
that almost three quarters (74%) of patients starting dialysis had left ventricular 
hypertrophy and almost one third had evidence of cardiac failure131.  
However, like with many other risk factors associated with CKD, the relationship between 
CKD and CVD potentially goes both ways. Analysis of pooled data from the ARIC Study35 and 
Cardiovascular Health Study132 showed that history of CVD at baseline was independently 
associated with increased likelihood of developing CKD and that patients who developed 
CKD were 10% more likely to have CVD than those who did not88. Progression defined as an 
increase in serum creatinine level by more than 35.4 μmol/L was also significantly more 
likely to occur in patients with CVD at baseline over a mean study period of nine years88; 
thus supporting the bidirectional relationship that patients with CKD are not only more 
likely to develop CVD but conversely patients with CVD are at increased risk of initially 
developing CKD and progressing if CKD is already present. On the other hand, it should be 
noted that this possibly causal association between CVD and CKD may at least in part due to 
confounding between shared risk factors such as hypertension and diabetes; although 







Proteinuria is a well-established promoter of progression in chronic kidney disease in 
patients with and without diabetes, and has been identified as the most important predictor 
of ESRD when compared to other potential clinical predictors such as BP and haematuria133. 
The pathogenetic mechanisms by which proteinuria, via both glomerular and 
tubulointerstitial injury, induces progressive decline in renal function include mesangial 
damage and protein accumulation within proximal tubule lysosomes.  This accumulation 
then damages tubular cells and leads to overexpression of pro-inflammatory markers which 
eventually culminates in fibrosis and consequent decline in GFR. Proteinuria is often present 
in conjunction with other risk factors such as age, diabetes mellitus, and hypertension which 
have been independently associated with it11. 
In more recent years the focus on proteinuria has narrowed to concentrate on albumin as 
the main contributor to renal damage and progression in CKD. Although worsening 
albuminuria itself is linked with declining renal function134, strong evidence from meta-
analyses have shown albuminuria to be independently associated with either accelerated 
progression rates or increased risk of ESRD and mortality in various different population 
groups at all stages of eGFR122,135–137. It is clearly demonstrated by the inclusion of 
albuminuria within the classification of CKD, that severity of albuminuria can be used as a 
discriminator for identifying patients at increased risk of progression. This is supported by 
findings from Gansevoort et al.135 whose systematic review on over one million patients 
from general and high risk populations associated worsening albuminuria with increasing 
rates of eGFR decline. For those with eGFR levels between 30-59 ml/min/1.73m2, all 
albumin to creatinine ratio categories were predictive of progression but for those with GFR 
stage 4 only ACR measurements greater than 10 mg/g were found to be predictive. 
However as normal urinary albumin loss is estimated to be 10 mg/g on average, this falls 
within the normal range and is not a particularly clinically significant finding. Similarly, 
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increasing ACR has been strongly associated with increased risk of progression to end-stage 
renal disease across stratified eGFR categories between 15-59 ml/min/1.73 m2 but is unable 
to accurately predict ESRD risk at eGFR >60 ml/min/1.73 m2 135. As mentioned above, for 
patients with both type 1 and type 2 diabetes, albuminuria is often the first clinical marker 
of renal dysfunction so unsurprisingly, of those with higher ACR levels, patients are more 
likely to be diabetic138. Despite this, when comparing patients with and without diabetes, 
the relative risk of progression to ESRD does not seem to be a significant difference 
between groups which therefore suggests absence of an additional interaction effect 
between albuminuria and diabetes122. Likewise, a similar relationship was noted between 
hypertension, albuminuria and mortality whereby, although the absolute risk of death 
increased in those with higher ACR and higher blood pressure, relative risks between 
hypertensive and non-hypertensive groups with regards to ESRD risk did not significantly 
differ136. 
 
2.2 Slowing Progression of CKD 
2.2.1 Glycaemic Control 
In diabetic patients, blood pressure control, albuminuria reduction and good glycaemic 
control are all potential intervention goals which may lead to reduction of progressive renal 
decline139. In this section we will focus on glycaemic control as albuminuria reduction and 
blood pressure control will be discussed later on. 
Evidence from several studies demonstrates that poor glycaemic control increases the risk 
of developing diabetic nephropathy and that good control can therefore delay the onset of 
developing renal dysfunction140,141. However, for many years it was uncertain whether or 
not intervention could alter the course of progression once patients developed 
microalbuminuria as results from several poor-quality observational studies showed no 
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evidence of improvement142–144. Strong evidence from one of the largest and most robust 
trials, the Diabetes Control and Complications Trial (DCCT)145, provided results which 
support the theory that more intensive glycaemic control can prevent progression of 
diabetic nephropathy, especially in patients with type 1 diabetes mellitus. Intensive therapy 
was shown to cause a significant reduction in HbA1c by 1.9% for the intensive treatment 
group in comparison to the conventional treatment group after two months. This lead to a 
lower incidence of microalbuminuria (albumin excretion rate ≥ 28 µg/min) and was also 
associated with a 15% relative reduction in albumin excretion rate after twelve months. 
Despite this, in patients with type 2 diabetes there is conflicting evidence on whether or not 
more stringent glycaemic control improves renal outcomes. Of two large clinical trials on 
patients with type 2 diabetes, the largest and most recent found a 20% reduction in the rate 
of new-onset or declining nephropathy alongside a reduction in microalbuminuria when 
comparing intense to standard control146 whereas the other reported no reduction in the 
risk of adverse renal events for the more intensively controlled group147. Regardless, the 
benefits of more intensive blood glucose control may be outweighed by the risk of harm. 
More intensive therapy is not only linked to increased rates of hypoglycaemia146 but has 
also been associated with increased cardiovascular morbidity and mortality in patients with 
CKD148. 
 
2.2.2 Managing Hypertension 
There is extensive RCT evidence from studies on CKD patients which demonstrates the 
benefits of lowering blood pressure for those with hypertension and CKD149. Blood pressure 
control not only ameliorates the risk of adverse cardiovascular events but also reduces the 
rate of progressive decline in renal function. The benefits of antihypertensive therapy are 
such that there is strong recent evidence which shows hypertensive patients on treatment 
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do not exhibit greater rates of ESRD or mortality when compared to normotensive 
patients136. 
However, with regards to determining the optimal BP target, as previously mentioned, RCT 
studies do not meet a consensus. While it is accepted that controlling hypertension to a 
normal BP goal of less than 140/90 mm Hg reduces risk of CKD progression in both diabetic 
and non-diabetic patients150, evidence on whether or not more intensive BP control at 
systolic goals less than 130 mm Hg can reduce the progression of chronic kidney disease is 
inconsistent. The MDRD study was unable to show a statistically significant benefit for a 
more intensive blood pressure target of less than 125/75 mm Hg, compared to the usual 
control target of less than 140/90 mm Hg, despite clinically significant findings which 
showed patients with higher levels of proteinuria progressed to ESRD at a rate that was 32% 
lower in the lower BP group compared to the standard BP control group after 10 years151. 
Results from the more recent REIN-2 trial in 2005 which defined the BP of the intensive 
treatment group as systolic BP <130 mm Hg plus diastolic BP <80 mm Hg and standard 
treatment as diastolic BP < 90 mm Hg did not show any clinically or statistically significant 
differences152. Rates of progression to ESRD were similar in both the intensive treatment and 
standard treatment groups, although the mean difference in BP between the two groups 
was only 4.1/2.8 mm Hg152. Similarly, results from the AASK trial demonstrated no significant 
differences in a cohort of African American patients, with regards to either the rate of GFR 
deterioration (relative eGFR reduction of 50% or absolute reduction of 25 ml/min/1.73m2) or 
risk of adverse outcomes (ESRD or death) between lower and usual BP control groups153. 
This contrasts with analysis of results from the Reduction of Endpoints in NIDDM with the 
Angiotensin II Antagonist Losartan (RENAAL) Study which showed a statistically significant 
6.7% reduction in the risk of progression to ESRD for every 10 mm Hg decrease in systolic 
blood pressure150.  A similar but slightly larger relationship was also seen in the Irbesartan 
Diabetic Nephropathy Trial (IDNT)149 which associated a systolic decrease of 20 mm Hg with 
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a 47% reduction in adverse renal outcomes. However, it was also noted that lowering 
systolic blood pressure in CKD patients to below 120 mm Hg did not confer any additional 
benefit with regards to preventing progression of CKD but additionally had an adverse 
outcome by increasing the proportion of all-cause deaths149 which were cardiovascular in 
nature154. More robust evidence from meta-analysis does however associate low BP with 
increased risk of progression but not until systolic blood pressure is below 110 mm Hg, not 
120 mm Hg. The lowest risk of progression was also found in the group with systolic BP 
between 110-129 mm Hg126, which contrasts results of individual RCTs some of which were 
discussed above. 
There is extensive RCT evidence which supports the use of ACE inhibitors in order to 
ameliorate cardiovascular risk and to slow the progression of renal function decline in 
CKD155–160. ACE inhibitors like ramipril and fosinopril not only help to reduce blood pressure 
but also reduce albuminuria in diabetic and non-diabetic CKD patients with 
albuminuria157,158. This contributes to their beneficial effect of reducing the risks of 
progressive decline or ESRD155. Meta-analysis has shown that the combination of blood 
pressure control and albuminuria reduction does not fully explain the overall reduction in 
CKD progression as the relative risks for ESRD and doubling of serum creatinine were 0.69 
and 0.70 respectively even following adjustment for systolic blood pressure and 
proteinuria155. ACE inhibition therefore provides additional benefits beyond the effect on 
blood pressure and albuminuria.  
For patients with diabetic nephropathy, the benefits of ARB and ACEi use have been widely 
studied161.  There is strong evidence supporting the use of ARBs; as investigated by Brenner 
et al. and Lewis, E. et al. in the IDNT162 and RENAAL163 studies. The angiotensin receptor 
blockers Losartan and Irbesartan are associated with relative reductions in CKD progression 
rates by 25% and 33% respectively162,163. The RENAAL study also reported that the risk of 
progressing to ESRD was 28% lower in the Losartan group which approximately equates to 
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deferring the need for dialysis or transplantation by 2 years162. Similarly to evidence on ACEi 
use in non-diabetic patients, the benefit of ARB use in limiting renal disease progression 
seems to exceed that attributable to its effect solely on lowering BP. However, ACE 
inhibitors are still the superior hypertensive drug class for diabetic patients as they 
demonstrate improved survival rates not seen with ARBs161. 
Whilst there is evidence from large clinical trials that using two RAS blocking drugs enhances 
the antiproteinuric effect of antihypertensive monotherapy, dual inhibition has not been 
shown to have any additional benefit for patients with CKD164. The risk of progression, ESRD 
or death does not improve with dual inhibition and instead has been shown to have adverse 
effects such as increased risks of hyperkalaemia, hypotension165 and acute kidney injury94. 
Renal function may also deteriorate164. 
 
2.2.3 Reducing Cardiovascular Risk 
In the management of CKD, the main methods of reducing cardiovascular risk are through 
antihypertensive therapy, as discussed above, as well as statin therapy. 
Statins have not been shown to reduce the progression rate of CKD in all patients but have 
been shown by one meta-analysis to slow the rate of eGFR decline in patients with CKD 
alongside cardiovascular disease by a rate reduction of 1.22 ml/min/1.73 m2 per year99. The 
use of statins is able to significantly reduce low density lipoprotein (LDL) levels and 
triglyceride levels leading to a significant reduction in total protein in patients with CKD100. 
This in turn may lead to reductions in albuminuria or proteinuria which Douglas et al.98 
suggests could be via the reduction of pre-existing endothelial dysfunction and by reducing 
vasoconstriction. For patients with pre-existing macroalbuminuria (or proteinuria >300 mg 
per day) statins can significantly reduce  their levels of proteinuria or albuminuria but for 
proteinuric patients with an excretion rate below the threshold of 300mg per day 
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reductions were not deemed to be statistically significant98. Although, these studies show 
that statins are able to reduce albuminuria and the rate of eGFR decline in patients with 
macroalbuminuria and pre-existing cardiovascular disease respectively98,99, statins have 
fewer significant benefits for the total CKD population. This is demonstrated by results from 
a more recent meta-analysis which did not show any significant improvement in risk of 
progression to ESRD, although it did show a 23% reduction in risk of cardiovascular 
events166. With regards to the reduction in CKD progression rate observed by Sandhu et al.99 
in patients with comorbid cardiovascular disease, it is likely that the benefit observed was 
attributable to the effect of Atorvastatin which has been shown to have superior lipid-
lowering effects than other statins as well as Cerivastatin100. However, regardless of 
whether statins do or do not lead to reductions in CKD progression rates in all CKD patients, 
there is no denying their ability to reduce risk of cardiovascular events166 and subsequent 
mortality100. 
 
2.2.4 Proteinuria Reduction 
The main method of proteinuria reduction is through the use of RAS inhibitors especially 
ACE inhibitors as discussed above. It was previously thought that reducing protein intake 
would provide benefits with regards to proteinuria reduction but low protein diets are no 
longer recommended. 
 
2.3 Impact of Secondary Care Referral 
2.3.1 Secondary Care and Progression Rates 
Only a few studies have explored the effect that nephrology care has on the progression 
rates of chronic kidney disease. Three studies published in 1999, 2002 and 2006 by Feest et 
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al.167, Joss et al.168 and Jones et al.169 respectively do this by using regression analysis to 
assess the rate of declining kidney function pre-referral and post-referral to nephrology 
clinics. Patients with diabetic nephropathy who receive care from a diabetic-renal clinic for 
at least 1 year are likely to see a slower rate of deterioration in renal function which was 
quantified as 0.25 ml/min per month improvement in creatinine clearance from baseline to 
3 years post-referral; although this difference was not found to be significant within a 
shorter time frame168. Otherwise, overall, referral to nephrology clinic was associated with 
an improvement in renal progression rates which have been quantified as either a reduction 
in the rate of eGFR decline from -5.4 ml/min/1.73m2 to -0.35ml/min/1.73m2 per year 169 or 
as a change in the slope of reciprocal serum creatinine measurements over time from -2.6 x 
10-6 to -1.5 x 10-6 167 in a mixed patient cohort and diabetic only cohort respectively. Despite 
this average improvement in renal decline of up 5 ml/min/1.73 m2 per year169, a large 
proportion of patients see no improvement at an individual level as demonstrated by 45%  
of patients who were identified as having a progressive rate of decline before referral 
continuing to progress at the same or an accelerated rate following referral169. Similarly, one 
cohort study published results which actually satisfied the concept of ecological fallacy 
whereby an association that exists at a population level does not exist at an individual level. 
Here, the slowed rate of deterioration was found to be significant in analysis of the whole 
group but was only significant in individual analyses for 39% of patients167. In theory this may 
be due to the variable progression patterns which differ between individuals or perhaps due 
to a significant proportion of patients in secondary care who have a propensity for steeper 
renal decline as a result of worse or more complex underlying disease. However, the 
differences in risk factors between ‘fast’ and ‘slow’ progressor groups were not statistically 
significant in a study which compared the two168. There was however, an increase in ACE 
inhibitor use to 81% from 50% which contributed to an absolute reduction in systolic blood 
pressure by 10 mmHg but again this was not statistically significant168. This is also 
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inconsistent with the findings by Jones et al. who found that lower systolic blood pressure 
was significantly associated with non-progression169. 
 
2.3.2 Timing of Secondary Care Referral 
There are multiple studies on how the timing of nephrology referral affects patient 
outcomes in patients with end-stage renal disease, usually in terms of mortality. Later 
referral is associated with a dose-response relationship with poorer patient prognosis as 
demonstrated by mortality rates at one, two and three years post first dialysis which show 
an increasing risk of mortality: 4.3%, 9.5% and 13.3% at year one; 14.6%, 22,4% and 27.6% 
at year two and 26.3%, 32.7% and 37.0% at year three for ‘early’, ‘intermediate’ and ‘late’ 
referral groups respectively170. This relationship between timing of referral and mortality 
rates is supported by several international cohort studies171–176 plus a meta-analysis of 
12,018 patients which quantified the increased relative mortality risk as  1.99 in patients 
referred ‘late’ compared to ‘early’ referrals177. This figure is only generalisable for mortality 
risk for up to one year due to differences in follow-up periods for included studies177 
although the improved survival of ‘early’ referral patients has been shown to be valid for up 
to 5 years follow-up174,178. 
Unsurprisingly, patients in late referral groups are more likely to be in a poorer state of 
health at the start of RRT compared to ‘early’ referrals as demonstrated by Jungers et al. 
whose ‘late’ referral patients had a substantially increased risk of requiring emergency 
dialysis due to uraemia (88% of late referral patients)179. Patients have also been noted to 
have a higher burden of co-morbid disease plus more abnormal baseline characteristics e.g. 
raised blood pressure, low levels of haemoglobin, reduced serum calcium and raised serum 
phosphate172. These factors are likely to increase the mortality risk experienced by ‘late’ 
referral patients and contribute to the more frequent complications of dialysis and 
50 
 
prolonged stays in hospital180. Patients referred ‘late’ or just lacking pre-ESRD nephrology 
care may also miss out on benefits such as education on dialysis modality which could 
influence patient choice and therefore be responsible for the reduced uptake of initial 
peritoneal dialysis compared to haemodialysis in late referral groups in some studies180. 
Permanent vascular access is also less likely to have been obtained prior to commencement 
of dialysis which may in turn lead to increased risk of complications such as sepsis179. 
Patients referred late are also less likely to receive or even be put on the waiting list for 
both living or cadaveric renal transplantation173,180,181. The greatest difference in transplant 
rates is noted to be within the first 3 months of referral181 which is likely due to poorer 
health in the early stages of dialysis in combination with limited time to adequately prepare 
the patient for transplantation. However, differences in transplantation rates remain 
significantly different for at least 2 years after initiating dialysis181. 
Early referral not only has clinical benefits but an economic one too. The costs of care in 
both the 6 months preceding and 12 months following initiation of RRT are lower in patients 
referred early compared to late referrals182. This is likely to be due to a number of factors 
such as the increased expenditures from prolonged hospitalisation in late referral 
patients183. 
 
2.3.3 Duration and Frequency of Secondary Care 
Cohort studies on the duration and quantity of nephrology care show that a longer duration 
of nephrology care is associated with better outcomes in end-stage renal disease. Following 
any duration of nephrology care patients are more likely to have favourable values of 
clinical markers such as serum albumin and haemoglobin, increased uptake of peritoneal 
dialysis and already established permanent vascular access as well as better access to renal 
transplantation184. The most favourable outcomes are found in patients with at least twelve 
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months of nephrology care184 although any duration of nephrology care before the initiation 
of dialysis can ameliorate the risk of mortality185. The frequency of visits to the nephrologist 
can also affect the mortality of patients with end-stage renal disease. Patients who had  
more than five visits in twelve months had a 15% improved survival rate171. However, the 
number of visits is no doubt inextricably linked with timing of the referral to nephrology 
care which would inevitably limit the possible number of nephrology visits which are 
feasible within the time available. Therefore the improved survival rate observed may again 




Chronic kidney disease is a complex condition in which complications of the disease may 
also cause it and/or accelerate its progression. This bidirectional relationship exists for the 
previously explored risk factors hypertension126, cardiovascular disease35 and proteinuria133; 
all of which are associated with an increased risk of progression88,126,133. The main methods 
of reducing the effects of these risk factors and therefore decreasing progression rates are 
through the control of blood pressure as well as blood sugar for diabetic patients145,149. 
Statin therapy especially the use of Atorvastatin can reduce the risk of cardiovascular 
mortality but may or may not reduce progression rates of CKD as results from meta-
analyses are inconsistent99,100,166. Proteinuria/albuminuria reduction may also be achieved 
through the use of antihypertensive agents such as ACE inhibitors which are a first-line 
hypertensive agent due to their enhanced effect on reducing progression rates2,155. 
Optimising the management of these risk factors, the goal of nephrology specialist care, 
overall is associated with slowing the decline of CKD although there may be a significant 
proportion of individuals in which this is not achieved167,169. Earlier referral to specialist care 
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has been shown to improve patient outcomes170. Any input from nephrology may increase 
survival rates but patients with a longer duration of care or more frequent visits are more 
likely to have better clinical biomarker values and reduced mortality171,184. However, 
currently the evidence on the timing of referral to specialist care, duration of care and 
frequency of care has been conducted on patients with or approaching ESRD. The 
generalisability of these findings to patients with CKD stage G3 patients is therefore 























CHAPTER 3: OBJECTIVES 
3.1 General Aim 
To investigate what the effect of care provided in different settings has on patients with CKD 
stage G3. In doing so we hope to provide evidence to either support or refute current NICE 
referral recommendations. 
 
3.2 Specific Objectives 
The key question we are aiming to answer is as follows: 
 What are the differences, if any, between CKD progression rates under primary care, 
renal secondary care and non-renal secondary care? 
Other aims of this thesis are to answer the following questions: 
 What are the differences, if any, between mortality rates under primary care, renal 
secondary care and non-renal secondary care? 
 What are the differences, if any, between rates of end-stage renal disease under 












CHAPTER 4: METHODS 
4.1 Data Sources 
The majority of the data for this dissertation was provided from two sources: the pathology 
database in the Royal Lancaster Infirmary and the EMIS database from Queen Square; a local 
GP practice. Raw data from each source was extracted by a single member of staff located 
within the pathology department or GP practice and then sent to the researcher and author 
of this work. A complete dataset was provided from Queen Square but the data from 
pathology was initially incomplete in two regards. Firstly, the pathology IT system underwent 
a system update in late 2010 so only data from January 2011 onwards was available for 
collection. Secondly, the pathology database only contains extractable data on the 
biochemical test results for patients treated in the Morecambe Bay area as well as some 
limited basic demographic information. The researcher was therefore required to collect 
further information on renal diagnoses, co-morbidities, medications and type of specialty 
care from an alternative source. This was done by accessing the electronic patient record via 
the program Lorenzo to view the records of patients who had been previously identified to 
be within the initial entry criteria of the research. 
Patients were initially categorised into primary or secondary care based on which database 
their records came from. There were 48 patients with records from both databases who 
were subsequently categorised as secondary care. Secondary care patients were subdivided 
into non-renal and renal care based on additional data collected as mentioned above.  
 
4.2 Entry Criteria 
The entry criteria were as follows: 
 2x eGFR measurements between 30-59 which are >90 days apart 
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o Date of entry (‘diagnosis’) to be the date of the first measurement 
 Both eGFR measurements to be within 01/04/2006 – 31/03/2014 
 Age > 18 years old 
 No active malignancy 
 
4.3 Manual Data Collection 
In order to gain a usable data set from a secondary care patient cohort which would not only 
be suitable for analysis but also be of a feasible size for manual data collection, the 
secondary care cohort for the study was limited to those treated in the Royal Lancaster 
Infirmary outpatient department. Thus, the manual data collection was restricted to patients 
who attended the Royal Lancaster Infirmary outpatient department only. 
Electronic patient records were accessed by conducting searches in Lorenzo using patient 
NHS numbers. Data was extracted by the researcher and author of this work by reading 
outpatient clinic letters written by medical consultants to GPs. These were only accessed if 
they fell within the study period of 01/01/2011 – 31/04/2014. Data was collected on date of 
death, medical specialty, renal replacement therapy type and date, renal diagnosis, number 
of antihypertensive medications by type as well as the co-morbidities: hypertension, 
diabetes and cardiovascular disease. Ideally the data was to be extracted from the single 
most recent letter. However, as the letter style varied greatly between specialties and the 
consultants within them, letters often contained inconsistent amounts of extractable data so 
additional letters were read from most to least recent until the information was gathered. 
For example if the most recent letter contained all the desired information, no further 
letters would be read. However if the most recent letter only contained information on co-
morbidities with no reference to medication, less recent letters would be accessed until 
medications were mentioned and the missing data would be extracted from that letter. If 
data was deemed to still be missing following scrutiny of all clinic letters in the allocated 
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study period, the researcher would then access the most recent hospital discharge summary 
to 31/04/2014 to provide this data if possible. Information on specialty type was then 
gathered by reading the full list of clinic letters and noting there origin by medical specialty. 
 
4.4 Reformatting 
The data provided from both primary and secondary care required considerable 
reformatting and cleaning.  This task was undertaken with the use of both Microsoft Excel 
and R: an open-source statistical software. The cleaning process involved the removal of 
data rows in multiple sweeps; leaving only data suitable for analysis in the final data set. For 
the secondary care data reformatting mostly consisted of data removal. Initially rows were 
removed if the patient had no eGFR values which reduced the data set from 1,302,469 rows 
to 555,324. Patients without two eGFR values were then excluded followed by those whose 
values were not more than 90 days apart as they therefore did not meet the entry criteria. 
As mentioned above, the dataset was then restricted to patients treated in the Royal 
Lancaster Infirmary outpatient department. 
On the other hand, the primary care data provided only included patients who had already 
met the entry criteria so reformatting instead consisted of converting the data into long 
format suitable for analysis as opposed to the exclusion of rows. Once combined with the 
secondary care data set, patients with active malignancy were also removed.  
Additionally, all eGFR values above 60 ml/min/1.73 m2 had to be calculated from serum 
creatinine measurements as the eGFR values were capped at this threshold. We did this 
using the MDRD equation which generated values which were comparable to our existing 
data set. Ranges of the data parameters were then inspected and if values were deemed to 
be clinically implausible that value only was also removed. 
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Figure 3 summarises the process of data cleaning.  
 
4.5 Statistical Software 
All data manipulation and analyses undertaken within this dissertation were performed 
using R, an open-source statistical software. The following additional packages were also 







4.6 Simple Linear Modelling 
In order to describe the relationship between two variables, one of the most common 
techniques is regression analysis. When modelling a continuous output, the most basic form 
of regression may be represented by the simple linear model which describes a straight line 
relationship between x, an input variable and y, an output variable. 
Raw data 
n=1,302,469 
Patients with at 
least one eGFR 
measurment 
n=555,323 







Medical wards and 
outpatient 
departments n = 
54,656 
Medical wards and 
OPD + removal of 
rows with missing 




Merge with primary 
care data n=16,971 
Removal of those 
with malignancy 
n=10,742 
Addition of eGFRs 
>59 and <30 
n=11,364 
Figure 3: Flow diagram of the data cleaning process 
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y = α + βx    (1) 
Here the intercept of the line is denoted by α and the gradient of the line by β. A positive 
value of β shows a relationship whereby an increase in x leads to an increase in y. Conversely 
a negative value of β shows the inverse of this relationship; with increasing x leading to a 
decrease in y. The remaining possible value for β is 0 which represents no relationship 
between the input and output variables x and y. This mathematical model (1) represents a 
perfect linear relationship and therefore cannot represent experimental data which is 
affected by random variation, often due to repeated measurements or experimental error. 
The statistical linear model (2) extends the mathematical model by adding the variable Z to 
represent this unpredictable random variation in experimental data. 
Y = α+ βx + Z     (2) 
Z measures the difference between the ‘line of best fit’, Y = α + βx, and an experimental 
result. Overall it should have a mean of zero and assumes independence between subjects. 
As Z is a random variable, y must also be affected by random variation so Y is capitalised in 
the statistical model to also show its stochastic nature186. 
Simple linear modelling was used to explore the relationships between eGFR and other 
potential explanatory variables at baseline. Continuous variables included age, albumin to 
creatinine ratio, haemoglobin, corrected calcium, albumin, alkaline phosphatase and 
phosphate. Binary variables included gender, ethnicity, smoking status, hypertension, 
cardiovascular disease and diabetes. Results can be found in sections 5.2 and 5.3. 
 
There a number of limitations to the simple linear model: 
1. It cannot model relationships between a continuous output variable, y, and a 
categorical input variable, x, with more than two categories. 
59 
 
2. Only one input variable can be modelled at a time so the simple linear model cannot 
account for multiple risk factors 
3. The model makes the assumption that measurements are independent of each 
other. This is not the case in longitudinal analysis where a single subject had 
repeated measurements over time. Thus a simple linear model cannot model 
longitudinal data. 
 
4.7 Multiple Linear Regression 
A multiple linear regression model is an extension of the simple linear model which tries to 
predict the relationship between a single output (dependent variable) and more than one 
input (explanatory) variable. In theory a multiple regression model may include an arbitrary 
number of explanatory variables and is therefore represented by the following equation: 
y = β0 + β1x1 + β2x2 + ... βkxk + Z     (3) 
As in the simple linear model β0 represents the intercept and Z represents the random 
variation. β1 represents the change in y for every unit change in x1 when all other 
explanatory variables (x2 ... xk) equal zero and likewise, β2 represents the same relationship 
for the variable x2. k represents the total number of input variables in the model
187. It is 
worth noting that in contrast to the simple linear model, multiple regression models are also 
able to incorporate categorical input variables with more than one outcome; not solely 
those which are continuous or binary. 
 
The 3 main situations in which you may want to perform a multiple regression analysis are: 
1. To explore the relationship between two variables by removing the effects of the 
other variables which are not considered important. 
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2. To explore the relationships between multiple variables when limited knowledge is 
available on which variables have prognostic interest. 
3. To develop a model which predicts an outcome of interest from several explanatory 
variables188. 
For this research, the third scenario is the most relevant. There are however several 
different methods which may be employed in order to develop a multiple regression 
model188. 
In this thesis, a forwards stepwise approach was used in order to try to construct a model to 
predict eGFR values at baseline. 
Initially all possible explanatory variables were fitted in order to construct a model with 
which all associations could be compared and therefore guide the order of which to add 
variables. A ‘null model’ with variables which were always to be included was then created. 
These often include variables already known to affect the outcome but our ‘null model’ only 
included the demographic variables age, gender and ethnicity. The variables deemed to have 
the greatest statistical (smallest p-values) and/or clinical significance were then added one 
at a time until an additional variable made no significant improvement to the model at the 
5% level (p<0.05). This was evaluated by maximum likelihood testing which is discussed in 
section 4.10. 
 
4.8 Linear Mixed Effects Modelling 
The main aim of this study is to compare the progression rates over time between primary 
and secondary care patients. As this uses longitudinal data, we cannot assume 
independence between measurements for the same individual patient, as previously done 
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when constructing simple linear and multiple regression models. Linear mixed effects 
models provide a solution to this problem. 
A linear mixed effects model allows for non-independence between experimental results by 
including both explanatory variables, henceforth referred to as ‘fixed’ effects, and ‘random’ 
effects with which to predict the outcome variable. The ‘fixed’ effects are those which have 
been measured and controlled in the experiment whereas ‘random’ effects refer to the 
unpredictable stochastic variation that is present within a study. Within health research this 
is often because of between-individual random variation due to differences between a 
patients underlying propensity to respond both at baseline and as a trajectory over a longer 
time period. A random intercept and random slope model in the form of 
Yij = α + βtij + Ui + Vitij + Zij     (4) 
predicts the outcome variable for the ith subject at the jth measurement. Here, U denotes the 
random variation in the intercept and V denotes the random variation in the slope189. U 
therefore represents the variation in baseline level of response between individual subjects 
and V represents the variation in their response over time. 
 
4.9 Residual Analysis 
Once a model has been constructed, it should be tested for its ‘goodness-of-fit’. By analysing 
the residuals we are studying how well the constructed model can predict the outcomes 
seen in the observed data. A single residual value is calculated by subtracting the predicted 
or fitted value from the model from the observed value: yobs – yfit .The assumption that 
residual values are normally distributed around a mean of zero can be verified by creating 
and inspecting the shape of a histogram of residuals.  
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A plot of the residuals against model-fitted values should show no relationship or 
recognisable pattern which therefore demonstrates a good fit for the model. Visualisation of 
this plot can also identify outliers within the study186. 
 
4.10 Likelihood 
The probability density function for a given set of parameter values show us that some data 
are more likely to be generated than others. The likelihood function is a reversal of this 
relationship which instead represents the probability of generating the observed data from a 
given parameter value, θ190. The value of θ which is most likely to generate the observed 
data is that which maximises the likelihood function and is known as the maximum 
likelihood estimate (MLE). For any other value of θ, we can conclude that its likelihood will 
be smaller than that of the MLE. A quantitative test of how many times smaller this is may 
be given by the likelihood ratio. If set to the MLE, this will take a value of 1 and less than 1 
for any other value of the parameter. The likelihood ratio can then be used to evaluate the 
performance of two competing statistical models and provide a formal guide to advise 
rejection or acceptance of the more complex model. 
By convention and computational convenience, the test statistic often denoted as D is 
calculated from the logarithm of the likelihood; which is also maximised by the MLE of the 
likelihood function. 
D = 2 x [L(likelihood for alternative model) – L(likelihood for null/simpler model)]     (5) 
This value may be referred to as the deviance or likelihood ratio statistic and can be 
interpreted for statistical significance by using a standard chi-squared test; whereby a p-
value below the given threshold for significance promotes the acceptance of the more 
complex model189. This technique was implemented at every stage of model construction. 
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CHAPTER 5: CROSS-SECTIONAL ANALYSIS RESULTS 
5.1 Description of the Study Population 
The following section aims to describe the study population with regards to distribution of 
demographic characteristics, co-morbidities and baseline biomarker data. Statistical 
significance was determined by conducting either a student’s t-test or a chi-squared test 
depending on the nature of the data (t-test for continuous and chi-squared for binomial 
data). The threshold for determining significance was a p-value less than 0.05. 
The total study sample included 1345 patients with CKD stage G3 at entry of whom 62.8% 
(n=845) were female compared to 37.2% (n=500) male. The patients with known ethnicity 
were almost exclusively white; with only 10 patients being of non-white ethnicity (see Table 
4). With regards to smoking history 398, 320 and 85 patients were classed as non-smokers, 
ex-smokers and current smokers respectively. However, there were a significant number of 
missing values for this risk factor. 
Table 4: Number of Patients by Ethnicity and Smoking Status 
 
 
From the total sample, 51.7% (n=695) and 48.3% (n=650) of patients were categorised into 
primary care or secondary care groups respectively. Those who had seen a secondary care 
specialist at least once within the study period were categorised as secondary care, 
otherwise patients were primary care. 
Of the co-morbidities, a history of hypertension was the most prevalent followed by history 
of cardiovascular disease and then diabetes, with prevalence rates of 56.7% (n=762), 38.7% 
(n=521) and 35.8% (n=481), respectively. The distribution of comorbidities by care group and 
gender is outlined in Table 5 below. 
Ethnicity White Non-White Not Stated  
984 10 351  
Smoking 
Status 
Current Ex-smoker Non-smoker Unknown 
85 320 398 542 
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Table 19 (see appendix) shows the mean, median, standard deviation (SD), range and 
interquartile range for each biomarker under study for the total population, males, females, 
primary care and secondary care. There are relatively large differences between the mean 
and median values for ACR and ALP which suggests that the data for these biomarkers may 
not be normally distributed. This can be seen by visualising the histograms found in Figures 4 
and 5 which additionally show eGFR as another variable with a non-normal distribution at 
baseline. In order explore the potential multiplicative effect, as opposed to additive effect, 
of ACR, ALP and eGFR at baseline we performed a transformation on to a logarithmic scale. 














762 (56.7) 290 (58.0) 472 (55.9) 447 (64.3) 315 (48.5) 
CVD (%) 521 (38.7) 235 (47.0) 286 (33.8) 280 (40.3)  241 (37.1) 
Diabetes (%) 481 (35.8) 212 (42.4) 269 (31.8) 221 (31.8) 260 (40.0) 
Figure 4: Histograms showing the distribution of values at baseline for the biomarker variables eGFR, ACR, Hb, 




Figure 5: Histograms showing the distribution of values at baseline for the biomarker 
variables ALP and serum phosphate 
In order to test whether differences between continuous variables for the care groups were 
significant, student’s t-tests were conducted. 
The average age of the total sample was 75.6 years at baseline but age differed significantly 
between the genders. On average, the female sample is significantly older than the male 
sample; with mean values of 76.1 and 74.7 years respectively and a p-value of 0.048. A 
similar relationship was also demonstrated between primary and secondary care patients 
whose average ages were 79.1 and 71.8 years respectively with a p-value of less than 0.001. 
No significant difference was found in the gender distribution between the care groups 
(p=0.057). 
Table 6: Description of baseline characteristics and biomarker data for the study population as a whole and 
then divided into primary and secondary care 
 Total 
Population 
Primary Care Secondary 
Care 
p-value 95% Confidence 
Interval 
Number (%) 1345 695 650   
Age in years (SD) 75.6 (12.2) 79.1 (11.17) 71.8 (12.26) <0.001 5.946-8.460 
eGFR (SD) 49.23 (8.03) 52.16 (6.17) 46.10 (8.59) <0.001 5.253-6.863 





132.8 (15.27) 124.1 (18.12) <0.001 6.430-10.916 
Corrected 
Calcium (SD) 
2.37 (0.13) 2.35 (0.10) 2.39 (0.14) <0.001 0.020-0.059 
Serum Calcium 
(SD) 
2.40 (0.14) 2.39 (0.11) 2.40 (0.16) 0.727 -0.026-0.018 
Albumin (SD) 41.35 (3.48) 42.05 (3.01) 40.56 (3.78) <0.001 1.069-1.906 
ALP (SD) 94.62 
(43.15) 
89.13 (36.77) 100.7 (48.62) <0.001 6.317-16.899 
Phosphate (SD) 1.12 (0.20) 1.12 (0.19) 1.13 (0.20) 0.718 -0.039-0.027 
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As one might expect, there were significant differences observed between primary and 
secondary care for the majority (75%) of the biomarker variables. These are laid out in Table 
6. Secondary care patients had worse renal function at baseline as demonstrated by a mean 
eGFR value significantly lower than that for primary care: 46.10 compared to 52.16 
ml/min/1.73 m2 with a p-value of less than 0.001. Similarly, average haemoglobin levels of 
132.8 and 124.1 g/L for primary and secondary care respectively were significantly different 
at the 0.1% significance level. Albuminuria levels were higher in secondary care: 8.49 
compared to 2.01 mg/mmol but at a lower significance level (p-value of 0.047). There were 
higher ALP levels in secondary care of 100.7 mmol/L compared to 89.1 mmol/l in primary 
care with a p-value of less than 0.001. On average, corrected calcium levels were 2.35 and 
2.39 mmol/L for primary and secondary care respectively with a p-value less than 0.001. 
Serum albumin was significantly lower in the secondary care group with mean values for 
primary and secondary care of 42.05 and 40.56 g/L respectively and a p-value less than 
0.001. 
 Table 7 below shows the number of patients with each comorbidity within primary and 
secondary care. In order to ascertain whether or not observed differences were statistically 
significant, p-values were determined by conducting chi-squared tests. For both 
hypertension and cardiovascular disease, significant differences in the proportion of patients 
with these comorbidities between primary and secondary care groups were present. 64.3% 
of primary care patients compared to 48.5% of secondary care patients had hypertension at 
a significance level of 0.1%; which shows a greater prevalence of hypertension in the primary 
care group. A similar relationship was demonstrated for cardiovascular disease with a 40.3% 
and 37.1% prevalence demonstrated for primary and secondary care respectively; although 
this was at a lesser significance level (p=0.002). Conversely, proportionally there were fewer 
patients with diabetes in the primary care group compared to the secondary care group: 
31.8% and 40.0% for primary and secondary care respectively with a p-value of 0.057. 
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However, as this is just above the threshold of 0.05, no statistically significant difference was 
found in the prevalence of diabetes between the two groups. 
Table 7: Prevalence of co-morbidities by total population and then split by care group 
 
Out of 1345 patients, 91 (6.8%) had a renal diagnosis other than diabetic or hypertensive 
nephropathy. Obstructive nephropathy was the most common followed by those with 
previous nephrectomy and then glomerulonephritis which accounted for 30.8%, 23.1% and 
19.8% of those with an additional renal diagnosis respectively. PKD and RAS accounted for 
6.6% and 7.7% respectively with the remaining 11 ‘other’ diagnoses consisting of patients 
with granulomatosis with polyangiitis, Alport syndrome, and congenital abnormalities such 
as absence or medullary sponge kidney. As might be expected, there were significant 
differences between the distribution of these primary renal diseases between primary and 
secondary care. Table 8 shows the number of patients with each renal diagnosis within 
primary and secondary care below. As with comorbidities mentioned above, p-values were 
calculated by chi-squared tests in order to determine the significance levels of the observed 
differences. 
Table 8: Prevalence of renal diagnoses by total population and then split by care group 







RAS (%) 7 (0.5) 0 (0) 7 (1.1) 0.018 
PKD (%) 6 (0.4)  0 (0) 6 (0.9) 0.033 
Obstructive 
Nephropathy (%) 
28 (2.1) 20 (2.9) 8 (1.2) 0.054 
Glomerulonephritis 
(%) 
18 (1.3) 0 (0) 18 (2.8) <0.001 
Previous 
Nephrectomy (%) 
21 (1,6) 0 (0) 21 (3.2) <0.001 
Other (%) 11 (0.8) 2 (0.3) 9 (1.4) 0.054 
Total (%) 91 (6.8) 22 (3.2) 69 (10.6) <0.001 







Hypertension (%) 762 (56.7) 447 (64.3) 315 (48.5) <0.001 
CVD (%) 521 (38.7) 280 (40.3)  241 (37.1) 0.002 
Diabetes (%) 481 (35.8) 221 (31.8) 260 (40.0) 0.057 
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With the exception of obstructive nephropathy, all renal diagnoses were more prevalent in 
the secondary care group. In fact, 100% of those diagnosed with renal artery stenosis, 
polycystic kidney disease, glomerulonephritis and previous nephrectomy were in receipt of 
secondary care; albeit at varying levels of significance. The differences between primary and 
secondary care for PKD and RAS were significant at the 5% level with p-values of 0.018 and 
0.033 respectively whereas glomerulonephritis and previous nephrectomy had statistical 
significance at a greater level of 0.1% (p<0.001). The diagnoses for which some patients 
were being treated under primary care only were not significant at the 5% level as both 
obstructive nephropathy and ‘other’ renal diagnosis had a p-value of 0.054 which is just 
above the threshold for significance at 0.05. 
Overall, if we accept the premise that in general patients in secondary care have been 
referred for a reason and therefore exhibit more complicated health issues, we might expect 
patients in secondary care to be younger and have a greater burden of renal or co-morbid 
disease. At baseline this is true for our study population with regards to average age and 
burden of renal disease as patients in secondary care were both significantly more likely to 
have a renal diagnosis and be younger compared to primary care patients; thus supporting 
this premise. However, with regards to the distribution of comorbid disease such as 
diabetes, hypertension and diabetes there was no clear cut distinction suggesting a higher 
prevalence in secondary care; although the burden is likely to have been underestimated in 
secondary care due to missing data. Regardless, the significant differences found baseline 
should be adjusted for before we can compare progression rates between care groups. 
 
5.2 Simple Linear Modelling of Continuous Variables 
 Simple linear models were constructed between potential continuous explanatory variables 
and eGFR (the response variable) in order to investigate the relationships between them and 
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their potential effects on renal function. The variables included were age as well as the 
biomarkers albumin to creatinine ratio, haemoglobin, corrected calcium, serum albumin, 
alkaline phosphatase and serum phosphate. Table 9 outlines the results below. 
 Table 9: Results of simple linear models of eGFR against potential continuous explanatory variables 
 
For the variable age, the linear model coefficient was -0.021 which would show that per year 
increase in age eGFR declines by 0.021 ml/min/1.73 m2 but the effect is not significant 
(p=0.242). 
The result for albumin-creatinine ratio again shows no relationship between it and eGFR. 
The linear model coefficient was -0.010 and the p-value was not significant (p=0.879). 
The linear model coefficient for haemoglobin was 0.132 which suggests that every unit (g/L) 
decrease in haemoglobin predicts a decrease in eGFR by 0.13 ml/min/1.73 m2. The result is 
significant at the 0.1% significance level (p<0.001). 
Per unit increase in corrected calcium, an eGFR decline of 6.54 ml/min/1.73 m2 is predicted 
by the linear model coefficient of -6.536. This result is just above the threshold for 
significance at the 1% level but is significant at the 5% level (p=0.017). However we cannot 
interpret this result as both extremes of calcium are linked with progression; a non-linear 
relationship which cannot be captured by a linear model. 
Variable Coefficient Standard Error p-value 
Age -0.021 0.018 0.242 
ACR -0.010 0.063 0.879 
Haemoglobin 0.132 0.016 <0.001 
Corrected Calcium -6.536 2.733 0.017 
Albumin 0.426 0.070 <0.001 
ALP -0.015 0.006 0.008 
Phosphate -5.159 1.812 0.005 
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There is a significant positive relationship between serum albumin levels and renal function. 
According to the simple linear model, for every 1 mg/mmol increase in albumin levels 
predicts an increase in eGFR by 0.43 ml/min/1.73 m2 with significance at the 0.1% level 
(p<0.001). 
The linear model for ALP shows a significant negative relationship between ALP and eGFR 
whereby a unit increase in ALP predicts a reduction in eGFR by 0.02 ml/min/1.73 m2 
(p=0.008). 
A significant relationship was found between serum phosphate and renal function at 
baseline. The linear model coefficient of -5.159 demonstrates a negative relationship. Per 
unit increase in serum phosphate, eGFR decreases by 5.16 ml/min/1.73 m2 (p=0.005). 
Overall, significant relationships were found between eGFR and five out of seven of the 
continuous explanatory variables investigated. Positive relationships were identified for 
haemoglobin and serum albumin whereas the relationships between corrected calcium, ALP 
and serum phosphate were negative. Surprisingly, no significant relationships were 
identified for age and albumin-creatinine ratio as reduced eGFR is more common with 
increasing age and ACR itself is associated with CKD disease progression. However, within 
the data set there are a lot of missing values for ACR which could explain this missed 
association.  
 
5.3 Simple Linear Modelling of Categorical Variables 
In order to explore the relationship between the response variable eGFR and categorical 
explanatory variables with two outputs, simple linear models were constructed in order to 
measure the association between them. The table below shows the results of these for the 
variables male gender, white ethnicity, positive history of smoking, hypertension, 
cardiovascular disease and diabetes. 
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Table 10: Results of simple linear models of eGFR against potential categorical explanatory variables 
Variable Coefficient Standard Error p-value 
Gender (Male) -0.158 0.453 0.727 
Ethnicity (White) 2.041 2.623 0.437 
Smoking (Positive History) -0.528 0.484 0.276 
Hypertension 0.144 0.442 0.744 
CVD -0.863 0.449 0.055 
Diabetes -0.804 0.457 0.078 
 
For male gender, the linear model coefficient was -0.158 which suggests that males have 
marginally lower eGFR values at baseline than females. However, this was not significant 
(p=0.727) and would have been of limited to no clinical relevance regardless. 
Being of white ethnicity was not found to be significantly associated with better renal 
function at baseline than non-white ethnicity. The linear model coefficient was 2.041 which 
suggests that white patients within the study sample would on average have eGFR values 
2.04 ml/min/1.73 m2 greater than those of non-white ethnicity (p=0.437). 
Patients with a history of smoking had eGFR values which were on average 0.53 ml/min/1.73 
m2 worse than patients who had never smoked. This was not found to be significant (p= 
0.276). 
The linear model coefficient for hypertension was 0.144 suggesting a slight improvement in 
eGFR for those with a history of hypertension. This was not statistically significant (p=0.744). 
History of cardiovascular disease had a coefficient value of -0.863 which on average suggests 
that those with a history of cardiovascular disease have slightly worse eGFR values at 
baseline than those without. However this was just above the 5% significant level (p=0.055). 
On average, patients with diabetes have eGFR 0.80 ml/min/1.73 m2 lower than patients 
without as demonstrated by its linear model coefficient of -0.804. This relationship was not 
found to be significant (p=0.078). 
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Overall, there were no statistically significant relationships discovered between eGFR and 
any of the binary variables. The lack of significant associations found between having a 
history of hypertension, cardiovascular disease or diabetes and renal function at baseline is 
perhaps a little surprising especially considering the causative nature of the relationship 
between hypertension or diabetes and chronic kidney disease. However, as previously 
mentioned, the burden of these comorbidities may not be accurate. 
 
5.4 Multiple Linear Regression Modelling 
Using the same baseline data as in sections 5.2 and 5.3, we now develop a multiple 
regression model for eGFR. A forwards stepwise regression approach was implemented and 
example R code may be found in the appendix. Initially a ‘full model’ using all potential 
explanatory variables was constructed with the exceptions of the biomarker ACR and 
categorical variable smoking status, which were omitted due to their high proportions of 
missing values (93.3% for ACR, 40.2% for smoking status). 
The table below shows the results of a model with main effects only, using data from 512 
patients. 
Table 11: Coefficients for the full multiple regression model for eGFR (ACR and smoking omitted) 
Variable Coefficient Standard Error p value 
(Intercept) 52.868 10.501 <0.001 
Care (Secondary) -7.435 0.877 <0.001 
Age -0.058 0.031 0.064 
Gender (Male) -1.576 0.754 0.037 
Ethnicity (Not Stated) 2.846 3.319 0.392 
Ethnicity (White) 4.301 3.227 0.183 
Haemoglobin 0.073 0.023 0.001 
Corrected Calcium -2.025 2.856 0.479 
Albumin 0.071 0.108 0.512 
ALP -0.010 0.008 0.224 
Phosphate -4.797 1.863 0.010 
Hypertension -0.985 0.710 0.166 
CVD 0.770 0.747 0.303 




Care group was both statistically and clinically significant within the model summarised in 
Table 11; with patients in secondary care having a 7.435 ml/min/1,73 m2 lower eGFR at 
baseline than primary care patients (p<0.001). In order to explore this association further, a 
second model was constructed which also accounted for any potential interaction effects 
between care group and other potential explanatory variables. Table 12 outlines the results 
below. 
Table 12: Coefficients for the full multiple regression model for eGFR accounting for interaction effects 
between care group and other explanatory variables 
Variable Coefficient Standard Error p value 
(Intercept) 54.793 18.579 0.003 
Care (Secondary) -9.090 20.969 0.665 
Age -0.053 0.031 0.093 
Gender (Male) -1.412 0.757 0.063 
Ethnicity (Not Stated) 2.526 3.307 0.445 
Ethnicity (White) 3.873 3.216 0.229 
Haemoglobin 0.083 0.044 0.064 
Corrected Calcium -6.976 5.796 0.229 
Albumin 0.088 0.201 0.661 
ALP -0.000 0.020 0.992 
Phosphate -0.288 3.269 0.930 
Hypertension 1.450 1.235 0.241 
CVD -0.357 1.234 0.772 
Diabetes 1.482 1.243 0.234 
Care*Haemoglobin -0.008 0.051 0.867 
Care*Corrected Calcium 5.858 6.657 0.379 
Care*Albumin -0.025 0.236 0.917 
Care*ALP -0.008 0.022 0.730 
Care*Phosphate -6.045 3.959 0.127 
Care*Hypertension -3.704 1.507 0.014 
Care*CVD 1.879 1.531 0.220 
Care*Diabetes -2.384 1.555 0.126 
 
The only significant interaction effect captured in this model was between care group and 
hypertension (p=0.014). Refitting without the non-significant interactions gave the model 





Table 13: Coefficients for the full multiple regression model for eGFR accounting for interaction effect between 
care group and hypertension only 
Variable Coefficient Standard Error p value 
(Intercept) 50.633 10.451 <0.001 
Care (Secondary) -5.102 1.182 <0.001 
Age -0.055 0.031 0.072 
Gender (Male) -1.529 0.749 0.042 
Ethnicity (Not Stated) 2.917 3.295 0.376 
Ethnicity (White) 4.302 3.203 0.180 
Haemoglobin 0.076 0.023 <0.001 
Corrected Calcium -2.188 2.836 0.441 
Albumin 0.077 0.107 0.474 
ALP -0.007 0.008 0.338 
Phosphate -4.747 1.849 0.011 
Hypertension 1.816 1.190 0.128 
CVD 0.719 0.742 0.333 
Diabetes 0.059 0.754 0.938 
Care*Hypertension -4.244 1.454 0.004 
 
We now define the ‘null model’ to include only the demographic variables age, gender and 
ethnicity. Other variables were then added in turn; the order of which to add next being 
based on the judgement of both the statistical and clinical significance of the variables from 
the ‘full model’, until further additions did not give a significant improvement in the fit. This 
resulted in the successive adding of care group, haemoglobin, phosphate and hypertension. 
The next variable, cardiovascular disease, made no statistically significant improvement to 
the model. Table 14 below shows the characteristics of the model prior to the inclusion of 
CVD. 
Table 14: Coefficients for the multiple regression model prior to refitting for eGFR 
Variable Coefficient Standard Error p value 
(Intercept) 46.947 5.644 <0.001 
Age -0.052 0.030 0.081 
Gender (Male) -1.355 0.724 0.062 
Ethnicity (Not Stated) 3.231 3.272 0.324 
Ethnicity (White) 4.586 3.178 0.150 
Care (Secondary) -5.280 1.163 <0.001 
Haemoglobin 0.080 0.021 <0.001 
Phosphate -4.578 1.831 0.013 
Hypertension 1.941 1.163 0.097 




In this model care group was the most clinically and statistical significant variable included 
with a coefficient of -5.280 and a p value of less than 0.001 which shows that secondary care 
is a predictor of lower eGFR values. Each unit increase in haemoglobin predicted an eGFR 
decline of 0.08 ml/min/1.73 m2 at the 0.1% significance level (p<0.001). Conversely 
phosphate shows a negative association whereby a single unit increase in phosphate 
predicts a reduction in eGFR by 4.58 ml/min/1.73 m2. This was also statistically significant 
but at a lesser significance level of 1% (p=0.013). Surprisingly, in this model hypertensive 
patients were predicted to have better eGFR values at baseline by 1.94 ml/min/1.73 m2 
which although not found to be statistically significant as its p value was just above the 
threshold of significance (p=0.097), may be clinically significant and did make a statistically 
significant improvement to the model. Accounting for the interaction effect between care 
group and hypertension reduced the magnitude of the care group coefficient to -4.373. 
In order to test the assumption that residual values are normally distributed, a histogram 
was constructed and inspected (see Figure 6 below). On visualisation, although not a perfect 
fit, it does seem to show a normal distribution; meaning that the assumption has been met 
in this model.  
 
Figure 6: Histogram of residual values for the constructed model 
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Plots of the residuals against the fitted values were constructed to evaluate the adequacy / 
goodness of fit of the model constructed. As previously mentioned, no demonstrable 
pattern should be seen; thus indicating good fit. Overall, the residual plot for the 
constructed multiple regression model shows no obvious discernible pattern of residuals and 










Figure 7: Plot of fitted values against residuals divided by care group 
It does however show a slight linearity between fitted and residual values which suggests 
that the model may have a propensity to underestimate higher eGFR values and 
overestimate lower values. It was suggested that this may possibly be due to uncaptured 
interaction effects between care group and the other biomarker variables which were not 
accounted for in the current model. However, comparison of the distribution of residuals for 
primary and secondary care patients shows no particular pattern and extending the current 
model to account for interaction between care group and haemoglobin or phosphate 
yielded no significant results; thus not supporting this theory. It is therefore more likely that 
this linear appearance is due to having an entry criterion which restricts baseline eGFR to 
between 30-59 ml/min/1.73 m2.  
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Overall, the final multiple regression model included the following variables: age, gender, 
ethnicity, care group, haemoglobin, phosphate, and hypertension. A significant interaction 
effect between care group and hypertension was present and accounted for within the 
model which demonstrated the absence of systematic error and satisfactory fit through the 




















CHAPTER 6: LONGITUDINAL ANALYSIS RESULTS 
6.1 Description of Longitudinal Data 
Here we aim to describe the data available for longitudinal analysis and provide the results 
of the initial exploratory analysis. 
As the main outcome variable of interest eGFR had no missing values due to the entry 
criteria, a record was considered to be incomplete if there were missing values for the non-
eGFR biomarker variables: haemoglobin, corrected calcium, albumin, alkaline phosphatase 
and phosphate. Similarly to in the multiple regression modelling performed in the cross-
sectional analysis, albumin to creatinine ratio was omitted again due to its high proportion 
of missing values (85.6%). 
Of the 11,364 records provided from 1,345 patients, there were only 4,530 complete records 
from 1,094 patients. Table 15 shows the number of complete records available per patient. 
Table 15: Breakdown of patients by number of complete records available 
 
Between one and five complete records were available for 844 patients of which 282 
patients had only one complete record. 149 patients had six to ten complete records, 70 
patients had between 11-15 complete records and 25 patients had 14-20. Only 6 had more 
than 20 complete records with the maximum number of complete records being 37. The 
mean number of complete records was 4.14, SD 4.11. 251 patients had zero complete 
records so were subsequently excluded from the linear mixed effects modelling to be 
discussed later. The ungrouped breakdown of complete patient records can be found in the 
appendix (Table 20).  
Number of Complete 
Records 
1-5 6-10 11-15 14-20 >20 
Number of Patients 844 149 70 25 6 
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Figure 8 shows the eGFR trajectories of a random sample of 50 patients overall and then 
split by care group. Here we can see that eGFR has different patterns in different patients. 
Whilst some patients demonstrate small variations in eGFR between measurements, others 
vary by over 50 ml/min/1.73 m2. Overall trajectories are also variable with some patients 
demonstrating improvement in renal function over time, others demonstrating progressive 
decline and others no particular change. There seems to be no obvious difference between 
patient trajectory patterns when comparing primary and secondary care. However, it should 
be noted that the lack of data beyond 3.3 years for most patients in secondary care is due to 


















Figure 8: Spaghetti plots showing the eGFR trajectories of a random sample of 50 patients and then 
split by care group 
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6.2 Preliminary Linear Mixed Effects Modelling 
In order to investigate any potential differences between primary and secondary care 
patients in a longitudinal analysis, we attempted to construct two different linear mixed 
effects models: one for primary care and another for secondary care. We did this by initially 
constructing normal multiple regression models which allowed us to exclude variables which 
were not likely to be significant in the mixed effects model and then converting these 
multiple regression models to linear mixed effects models in order to account for the non-
independence between longitudinal measurements. Variables which were no longer 
significant post-conversion were excluded from the mixed effects model. Tables 16 and 17 
show the characteristics of the mixed effects models for primary and secondary care 
respectively. 
Table 16: Linear mixed effects model for primary care only 
Fixed Effects Value SE p-value Random SD Corr 
Intercept 76.807 6.719 <0.001 Intercept 5.505  
Age -0.280 0.036 <0.001 Time 2.914 0.322 
Gender(Male) 0.107 0.809 0.895 Residual 7.861  
Ethnicity 
(Unknown) 
10.800 3.819 0.005    
Ethnicity (White) 13.230 3.797 <0.001    
Time (years) 1.822 0.185 <0.001    
Diabetes 15.852 5.875 0.007    
Albumin -0.184 0.107 0.086    
Phosphate -7.604 1.204 <0.001    
Diabetes:Albumin -0.334 0.138 0.016    
 
The primary care mixed effects model included 2,827 complete records from 568 patients. It 
shows that for every per year increase in a patients baseline age, eGFR declines by 0.28 
ml/min/1.73 m2 (p<0.001). Males had a marginally higher eGFR (0.10 ml/min/1.73 m2) than 
females but this was not statistically significant (p=0.895). Patients of white ethnicity had 
eGFR values 13.23 ml/min/1.73m2 greater than those of non-white ethnicity and this was 
statistically significant (p<0.001). Each single unit increase in phosphate predicted a 7.60 
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ml/min/1.73 m2 reduction in eGFR (p<0.001). The model shows a significant interaction 
effect between diabetes and albumin levels whereby albumin levels are predictive of 
diabetes effect on patients’ renal function. Surprisingly, per unit increase in albumin is 
associated with a 0.33 ml/min/1.73 m2 reduction in eGFR for diabetic patients only. 
However, overall relationship between diabetes and eGFR is likely to be positive. Based on 
the mean albumin level of primary care patients (41.21 g/L), those with diabetes have eGFR 
values 2.09 ml/min/1.73 m2 greater than patients without diabetes. Albumin does not have 
a significant effect on its own. 
Overall, patients in primary care seemed to show improvement in renal function over time 
with an eGFR increase of 1.82 ml/min/1.73 m2 per year. 
Table 17: Linear mixed effects model for secondary care only 
Fixed Effects Value SE p-value Random SD Corr 
Intercept 61.165 6.435 <0.001 Intercept 8.708  
Age -0.109 0.041 0.007 Time 3.529 0.125 
Gender(Male) -0.645 0.975 0.509 Residual 6.660  
Ethnicity (Unknown) -0.043 5.373 0.994    
Ethnicity (White) 1.546 5.212 0.767    
Time (years) 0.827 0.321 0.010    
Diagnosis (RAS) -11.348 4.142 0.006    
Diagnosis (Nephrectomy) -3.631 2.649 0.171    
Diagnosis (PKD) 1.713 4.898 0.723    
Diagnosis (Other) -6.675 3.639 0.067    
Diagnosis (Obstructive 
Nephropathy) 
-7.276 4.686 0.121    
Diagnosis 
(Glomerulonephritis) 
-5.793 2.601 0.026    
Phosphate -9.549 1.273 <0.001    
Haemoglobin 0.037 0.018 0.047    
Hypertension -2.202 0.946 0.020    
 
The secondary care mixed effects model was fitted to 1,703 complete records from 526 
patients. It shows that for every per year increase in a patients baseline age, eGFR declines 
by 0.11 ml/min/1.73 m2 (p=0.007). Males had a marginally reduced eGFR which was 0.65 
ml/min/1.73 m2 lower than females but this was not statistically significant (p=0.509). 
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Patients of white ethnicity had eGFR values 1.55 ml/min/1.73m2 greater than those of non-
white ethnicity but again this was statistically significant (p=0.767). Each single unit increase 
in phosphate predicted a 9.55 ml/min/1.73 m2 reduction in eGFR (p<0.001). For secondary 
care patients, two renal diagnoses were associated with having poorer renal function. 
Patients with either renal artery stenosis or glomerulonephritis had poorer eGFR than those 
without by 11.35 ml/min/1.73 m2 (p=0.006) and 5.79 ml/min/1.73 m2 (p=0.026) respectively. 
The results from other renal diagnoses within the model were not significant at the 5% level. 
Per unit increase in haemoglobin was associated with a 0.04 ml/min/1.73 m2 improvement 
in renal function (p=0.047). Patients with hypertension had eGFR which was 2.20 
ml/min/1.73 m2 lower than those without (p=0.020). No significant interaction effects 
between variables were found. 
Overall, patients in secondary care show a 0.83 ml/min/1.73 m2 improvement in renal 
function per year (p=0.010). 
If we compare the intercepts of both models, patients in primary care are likely to have a 
higher starting level of eGFR: 76.81 ml/min/1.73 m2 for primary care compared to 61.17 
ml/min/1.73 m2 in secondary care. Only age and serum phosphate were found to be 
significant in both models and whilst the magnitude of the effect of age is slightly greater in 
primary care, the effect of phosphate is greater in secondary care. Surprisingly patients with 
diabetes are likely to have better renal function, dependent on their albumin levels, than 
those without in primary care only. Conversely, whilst no interaction effects were found in 
secondary care, additional different variables were found to be significant. Having an 
existing renal diagnosis specifically renal artery stenosis or glomerulonephritis, poorer 
haemoglobin levels and having hypertension were significantly associated with poorer renal 
function in secondary care. By identifying the different variables which were statistically 
significant for one model but not the other e.g. diabetes in the primary care model, we have 
identified some variables which may potentially interact with care group in the overall 
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combined population model. These include diabetes, diabetes*albumin, renal diagnosis, 
haemoglobin and hypertension. 
 
6.3 Final Mixed Effects Modelling 
We created a linear mixed effects model for the total study population by adding the 
variable care group and then automatically including the baseline demographic variables 
such as age, gender and ethnicity plus any variable which was found to be significant in 
either the primary or secondary care model. Potential interaction effects between care 
group and the variables unique to one model as discussed above were explored for 
statistical significance before deeming the variable as insignificant and excluding it. 
Hypertension as a variable was recoded to account for the treatment effect of 
antihypertensive agents which have been shown to reduce progression rates to the same 
level as those without hypertension. The new binary variable for hypertension instead refers 
to patients diagnosed with hypertension but receiving no antihypertensive therapy instead 
of the crude previous delineation of diagnosis of hypertension or not. Similarly we recoded 
care group into a three-way categorical variable by splitting secondary care patients into 
those who were seeing a renal specialist or not. This was to allow us to make a more in 
depth comparison of the effect of secondary care on renal function. The characteristics of 
the overall model can be found below in Table 18. 
Table 18: Linear mixed effects model for total population 
Fixed Effects Value SE p-value Random SD Corr 
Intercept 74.604 5.983 <0.001 Intercept 6.854  
Age -0.214 0.027 <0.001 Time 2.964 0.249 
Gender(Male) -0.122 0.628 0.856 Residual 7.458  
Ethnicity (Unknown) 4.860 3.111 0.118    
Ethnicity (White) 7.164 3.069 0.020    
Time (years) 1.834 0.186 <0.001    
Diagnosis (RAS) -6.642 3.721 0.075    
Diagnosis (Nephrectomy) -3.230 2.346 0.169    
Diagnosis (PKD) 4.509 4.304 0.295    
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Diagnosis (Other) -4.422 2.853 0.121    
Diagnosis (Obstructive 
Nephropathy) 
-0.780 1.963 0.691    
Diagnosis 
(Glomerulonephritis) 
-0.042 2.383 0.986    
Phosphate -7.910 0.885 <0.001    
Haemoglobin 0.058 0.014 <0.001    
Albumin -0.278 0.108 0.010    
Untreated Hypertension -1.582 0.821 0.054    
Diabetes 16.693 5.851 0.004    
Care (Secondary Non-renal) -0.389 6.433 0.952    
Care (Secondary – renal) -12.374 10.356 0.232    
Time:Care (Secondary Non-
renal) 
-0.960 0.400 0.017    
Time:Care (Secondary Renal) -2.005 0.651 0.002    
Albumin:Diabetes -0.344 0.137 0.012    
Diabetes:Care (Secondary 
Non-renal) 
-17.196 9.113 0.059    
Diabetes:Care (Secondary 
Renal) 
















0.372 0.208 0.074    
 
The total population mixed effects model was fitted to 4,530 complete records from 1,094 
patients. It shows that for every per year increase in a patients baseline age, eGFR declines 
by 0.21 ml/min/1.73 m2 (p<0.001). Males had a marginally reduced eGFR which was 0.12 
ml/min/1.73 m2 lower than females but this was not statistically significant (p=0.856). 
Patients of white ethnicity had eGFR values 7.16 ml/min/1.73m2 greater than those of non-
white ethnicity and this was statistically significant (p=0.020). Despite being significant in the 
secondary care model, results from the total population model show no specific renal 
diagnosis significantly affects renal function at the 5% level. However, patients with renal 
artery stenosis had poorer eGFR than those without by 6.64 ml/min/1.73 m2 although this 
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was just above the threshold for significance (p=0.075). Each single unit increase in 
phosphate predicted a 7.91 ml/min/1.73 m2 reduction in eGFR (p<0.001). Per unit increase 
in haemoglobin was associated with a 0.06 ml/min/1.73 m2 improvement in renal function 
(p<0.001). Patients with untreated hypertension had eGFR which was 1.58 ml/min/1.73 m2 
lower than those without but this was just above the threshold for statistical significance 
(p=0.058).  
Similarly to the primary care model, interaction effects were observed involving diabetes in 
either a two-way interaction between albumin or in a potential three-way interaction also 
involving care group. Individually the variables care group, diabetes and albumin were all 
associated with significant effects on renal function. Each single unit increase in albumin was 
significantly associated with a 0.28 ml/min/1.73 m2 increase in eGFR (p=0.010). Without 
accounting for the interaction between diabetes and albumin, having diabetes in primary 
care was associated with a statistically significant increase in eGFR by 16.69 ml/min/1.73 m2 
(p=0.004); in contrast to secondary care in which a diagnosis of diabetes was associated with 
0.50 ml/min/1.73 m2 (p=0.059) and 1.22 ml/min/1.73 m2 (p=0.182) reduction in eGFR 
depending whether patients were under non-renal or renal specialist care respectively. The 
interaction effect between albumin and diabetes associates a per unit increase in albumin 
with a 0.34 ml/min/1.73 m2  reduction in eGFR if diabetic which would reduce the beneficial 
effect of diabetes on renal function to 2.36 ml/min/1.73 m2 based on a mean albumin level 
for primary care of 41.68 g/L. In contrast to this finding, increasing albumin levels and thus 
better nutritional status, were associated with improvements in eGFR by 0.37 ml/min/1.73 
m2 per unit increase in albumin in diabetic patients under renal specialist care although this 
was just above the threshold for statistical significance (p=0.074). The interaction between 
albumin and diabetes in the secondary non-renal care group was not remotely significant 
but there is an almost significant interaction between secondary non-renal care and diabetes 
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which associates diabetes with worse renal function than those without by 0.50 ml/min/1.73 
m2. 
No additional interaction effects were found between care group and any other variables.  
 
Figure 9: Plot showing the overall eGFR trajectories of primary care, secondary non-renal care and secondary 
renal care patients with 15 simulated individual patient trajectories per group 
Figure 9 above shows the trends of renal function over time by care group based on a 
starting eGFR of 50 ml/min/1.73 m2 for primary care patients. The bold red, blue and green 
lines show the overall trajectories for primary, secondary non-renal and secondary renal 
care respectively. Additionally there are 15 simulated patient lines included for each care 
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group. Secondary care patients under non-renal specialists had a non-significant difference 
in baseline renal function compared to primary care patients which was -0.39 ml/min/1.73 
m2 (p=0.952). Patients receiving care from renal specialists also had worse renal function at 
baseline which was 12.37 ml/min/1.73 m2 lower than primary care patients but again this 
was not significant (p=0.232) .The overall trajectories of primary care patients and secondary 
non-renal patients showed improvement in renal function. In primary care this was an 
improvement in eGFR by an average of 1.83 ml/min/1.73 m2 per year (p<0.001) but in non-
renal secondary care patients renal function improved by a lesser rate of 0.87 ml/min/1.73 
m2 per year. In contrast, patients who received care from a renal specialist showed a decline 
in renal function by a rate of 0.17 ml/min/1.73 m2 per year.  
The weighted average for the study population was 1.26 ml/min/1.73 m2. 
 
6.4 Residual Diagnostics 
Figures 10 and 11 are plots used for the residual diagnostics for the combined model. Figure 
11 shows no clear pattern and Figure 10 shows a normal distribution of residuals which 
therefore demonstrates a good fit for the model and thus the absence of systematic error. 
However as Figure 11 shows increasing variance with increasing fitted values, if we had not 
been constrained by time pressures we would have liked to log-transform the output 
variable eGFR in order to reduce the variability and therefore improve the model fit. 
Residual diagnostics for the primary and secondary care only models can be found in the 





6.5 Patient Mortality, Progression to ESRD and Initiation of RRT 
Overall there were 227 patient deaths over the study period of up to 8 years of which 152 
were primary care patients and 75 were secondary care. Crude mortality rates for the 
respective groups are therefore 16.9%, 21.9% and 11.5% for the total population, primary 
care and secondary care. As primary care patients had a study period greater than that of 
secondary care, we then restricted analysis of primary care patients to those who died 
within the first 3.3 years (the study period for secondary care) in order to make figures 
comparable. Comparable mortality rates were 7.4% (n=100), 4.3% (n=30) and 10.8% (n=70) 
for the total population, primary care and secondary care respectively. The difference in 
mortality rate between primary and secondary care is equivalent to a 2.49 times increased 
risk of death for the secondary care group (95% CI = 1.65-3.77). This was significantly 
different at the 0.1% level. Of the secondary patients who died, only 10% (n=7) were under 
renal specialist care. The relative risk of death for renal compared to non-renal patients in 
secondary care was 0.50 (95% CI = 0.23-1.06). 
In total 10 patients progressed to ESRD in the study period which is a total population 
incidence rate of 0.74%. According to our data, most of these patients were under primary 
care (60%, n=6) and those under secondary care were split evenly between non-renal (20%, 
Figure 10: Histogram of residual values for the total 
population linear mixed effects model 
Figure 11: Residual plot for the total population 
mixed effects model 
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n=2) and renal specialists (20%, n=2). Crude rates for the incidence of ESRD in primary and 
secondary care were 0.86% and 0.62% respectively. Once restricted to a period of 3.3 years 
the incidence rates of ESRD were 0.30% (n=4), 0.14% (n=1) and 0.46% (n=3) respectively for 
the total population, primary care and secondary care. The relative risk for secondary care 
compared to primary care was 3.21 (95% CI = 0.33-30.76) but this was not significant. 
However, renal secondary care patients were 8.92 times more likely to progress to ESRD 
than non-renal secondary care patients (95% CI = 0.81-97.61) but as the confidence interval 
includes 1 this result cannot be seen as statistically significant. 
Of the patients who progressed to ESRD we know that one went on to receive haemodialysis 
and then renal transplantation and that another also had a transplant but additional data on 
the other patients is missing. We therefore cannot make any comparisons or conduct any 
analyses between care groups for RRT.  
 
6.6 Summary 
Patients with CKD stage G3 not under renal specialist care show an overall improvement in 
renal function over time which is equivalent to improvements of 1.83 ml/min/1.73 m2 or 
0.87 ml/min/1.73 m2 per year in eGFR for primary care and non-renal secondary care 
patients respectively. Conversely, patients receiving renal specialist care decline at an overall 
rate of 0.17 ml/min/1.73 m2 per year. Increasing age, non-white ethnicity, higher phosphate 
levels, lower haemoglobin levels and higher albumin levels were significantly associated with 
poorer renal function whilst surprisingly diabetes was associated with greater renal function 
in primary care which to some extent may be influenced by albumin levels. Patients in 
secondary care have a significantly increased risk of mortality compared to primary care 
patients which is equivalent to a relative risk of 2.5 although a substantial portion of this risk 
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may be attributed to patients in non-renal secondary care. Similarly, those who progress to 























CHAPTER 7: DISCUSSION AND CONCLUSIONS 
7.1 Discussion 
This is the first study to attempt to compare patterns of renal function in CKD G3 patients in 
different care settings so we have no other literature with which to directly compare our 
results.  
 
Patients in secondary care have worse biomarker values at baseline 
With the exceptions of serum calcium and phosphate levels, patients in secondary care had 
biomarkers which were both significantly different and suggestive of worse or slightly 
further progressed disease compared to primary care patients. 
Haemoglobin levels were significantly lower for secondary care patients which is suggestive 
of a higher prevalence of anaemia in secondary care patients although levels were within 
normal parameters (132.8 g/L in primary care and 124.1 g/L for primary and secondary care 
respectively). Albuminuria levels at baseline support the notion that secondary care patients 
are at greater risk of progression as on average secondary care patients had albuminuria 
6.48 mg/mmol greater than primary care patients. There may also be a greater prevalence 
of metabolic acidosis and therefore perhaps CKD metabolic bone disease in the secondary 
care population which can be inferred by the higher ALP levels in secondary care of 100.7 
mmol/L compared to 89.1 mmol/l in primary care. Lower albumin results in secondary care 
compared to primary care suggest that secondary care patients have poorer nutritional 
status. On average, corrected calcium levels were 2.35 mmol/L and 2.39 mmol/L for primary 
and secondary care respectively. Although this difference was statistically significant, as CKD 
may cause both hypo- and hypercalcaemia, the clinical interpretation of these results is 
difficult. This could be due to a greater prevalence of secondary hyperparathyroidism in the 
secondary care group or due to the presence of a solitary individual with worse disease. 
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However, as the spread of data for secondary care is greater than primary care this is hard to 
determine. 
 
Overall trends of renal function are significantly different between care groups. 
At baseline patients in secondary care had eGFR which was 6.06 ml/min/1.73 m2 significantly 
worse on average than patients in primary care. This difference is likely to be due to having a 
higher proportion of patients with worse renal function in renal secondary care as results 
from longitudinal analysis suggest that on average renal secondary care patients have eGFR 
which is 12.37 ml/min/1.73 m2 worse than patients under primary care. Although this 
finding was not statistically significant, this difference is large enough to be clinically 
significant unlike the difference of -0.39 ml/min/1.73 m2 for patients in non-renal secondary 
care which is statistically significant but unlikely to be clinically relevant. The total population 
demonstrated an average improvement of 1.26 ml/min/1.73 m2 per year over a mean follow 
up period of 2.84 years. Both primary care patients and non-renal secondary care patients 
demonstrated improvements in renal function over time by rates of 1.83 ml/min/1.73 m2 
per year and 0.87 ml/min/1.73 m2 per year respectively. This is in contrast to a decline in 
renal function demonstrated by patients seeing renal specialists in secondary care by 0.17 
ml/min/1.73 m2 per year. 
There are three possible ways to interpret these findings: 
1. Patients in renal specialist care are deteriorating because the care they receive is 
different to that provided by the other care groups 
2. Patients under renal specialist secondary care themselves have a greater propensity 
to decline 
3. Patients in renal secondary care are further along in the disease process 
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To even consider the first interpretation would be ill-advised as previous studies have shown 
the benefits of nephrology care with regards to slowing progression rates, increasing survival 
and increasing access to transplantation in patients with ESRD. We therefore focus on trying 
to explore the latter two explanations. 
 
Differences in renal function trends between care groups cannot be attributed to a greater 
burden of comorbid disease in secondary care patients. 
It may be assumed that patients in secondary care have a greater burden of comorbid 
disease or more complex health needs and therefore have worse health than patients in 
primary care. However, according to our data, with regards to the prevalence of 
hypertension and cardiovascular disease the reverse was true. Primary care patients had 
significantly higher prevalence rates of these comorbidities which were 15.8% and 3.2% 
higher for hypertension and cardiovascular disease respectively in comparison to secondary 
care. For diabetes prevalence rates were greater in secondary care but this was not found to 
be statistically significant. Additionally, hypertension and cardiovascular disease did not have 
a significant impact on renal function within the linear mixed effects model which would 
suggest that for CKD stage G3 patients either these risk factors do not affect renal function 
or perhaps that the management of these risk factors had already been optimised. As there 
is already extensive literature which demonstrates the relationship between hypertension or 
vascular disease as risk factors for progression in CKD patients, we therefore propose the 
latter explanation but cannot ignore that the burden of comorbid disease likely to have been 
underestimated in secondary care. 
Diabetes was shown to have a more complex relationship with renal function in the linear 
mixed effect model which shows that it may or may not be dependent on albumin levels and 
care group. Contradictorily, it seems to suggest that better nutritional status was associated 
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with worse renal function of diabetic patients in primary care but improved renal function in 
patients in secondary care under renal specialists. We cannot discount that this finding may 
just be the result of statistical artefact but the author of this work deems the interpretation 
of this to be beyond their current level of knowledge on the subject and would therefore like 
to consult the specialist renal community before commenting on this finding.  
 
Differences in renal function trends between care groups cannot be attributed to a greater 
burden of known progressive renal diseases. 
We know from previous studies that the underlying aetiology of chronic kidney disease can 
have an impact on patient survival and likelihood of progression to end-stage renal 
disease117,118. Preliminary modelling seemed to support this  within the secondary care 
model as diagnoses of renal artery stenosis and glomerulonephritis were significantly 
associated with comparatively worse renal function to those without by 11.35 ml/min/1.73 
m2 and 7.28 ml/min/1.73 m2 respectively. Renal diagnosis had no significance within the 
primary care model but this was not surprising as the greatest burden of patients with these 
was within secondary care. Despite being significant in secondary care, within the total 
population model no specific renal diagnoses demonstrated a significant impact on renal 
function. The effect of renal artery stenosis was the closest to being significant with a p-
value of 0.075 and lesser negative effect on renal function compared the secondary care 
model of 6.64 ml/min/1.73 m2. As the effects on renal function from different renal 
diagnoses were not significant within the full model, we cannot attribute the differences in 
pattern of renal progression to differences in burden of known progressive renal diagnoses 
for our study population. However, it is possible that this lack of significance is due to the 




Differences in renal function trends between care groups cannot be attributed to 
differences in antihypertensive therapy use. 
Untreated hypertension was shown to have an adverse effect on renal function. Patients 
with untreated hypertension on average had renal function which was 1.58 ml/min/1.73 m2 
worse than patients who did not. Although this was just above the level for statistical 
significance (p=0.054), this finding is supported by extensive evidence showing the benefits 
of antihypertensive therapy especially ACE inhibitors and ARBs which reduce progression 
rates and also reduce albuminuria126,152,153,155. However, the lack of interaction with time or 
care group for this variable showed that it did not increase the rate of progression and that 
its effect was similar in all care groups. This finding is perhaps a little surprising, considering 
that antihypertensive therapy is often the main method of ameliorating renal progression so 
a lack of treatment would in theory promote faster deterioration in renal function. It is 
worth noting that in our study diagnoses of untreated hypertension were given based on 
written records of patient diagnoses not on clinical blood pressure measurements. Thus, it is 
entirely plausible that some patients categorised as having untreated hypertension did not 
have a current diagnosis of hypertension and therefore did not require anti-hypertensive 
therapy. If this was the case, the eGFR patterns may have counteracted the increased 
progression rates which may have been demonstrable and therefore explain the lack of 
increased progression rates seen in patients with untreated hypertension. 
 
Stage G3 CKD is not inherently progressive. 
As far as we are aware, this is the first study to demonstrate a small overall population level 
improvement for patients with CKD stage G3. These results therefore add to the growing 
theory that chronic kidney disease is not an inherently progressive condition and that there 
is a lot of variability between individuals. This hypothesis was first speculated following the 
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Modification of Diet in Renal Disease151 study which observed improvement or non-
progression of renal decline in up to 19% of patients with GFR 25-55 ml/min/1.73 m2 over 
the two year study period. A more recent longitudinal observation study which focused 
solely on patients with CKD stage G3 (GFR 30-59 ml/min/1.73 m2) for an average of four 
years demonstrated an even greater proportion of favourable outcomes as 27% of patients 
showed no evidence of progressive decline20. In fact, the proportion of non-progressing CKD 
3 patients may be even greater as one retrospective cohort study has shown that up to 
48.1% of patients with CKD 3 did not progress and instead showed either maintenance or 
improvement in renal function over a 10 year follow-up period22. Even higher rates of non-
progression have been found in up to 96% of a UK population of patients with CKD stage G3 
who demonstrated non-progression rates of 76% alongside an improvement rate of up to 
20% of those studied between 2001 to 2004191. 
 
Our study population showed an overall improvement in renal function by 1.26 
ml/min/1.73 m2. 
We cannot ignore the fact that published evidence shows an overall decline in renal function 
at a population level which is in contradiction to our findings. Other studies showed rates of 
renal function decline between 1.0-5.4 ml/min/1.73 m2 per year20,192,193. This suggests that 
within our study perhaps there were a larger proportion of non-progressing or improving 
patients than compared to other studies but unfortunately as we did not conduct analyses of 
individual patient trajectories we cannot confirm this assumption. Additionally as we do not 
know how many patients within our study population maintained stable renal function or 
improved we cannot directly compare our figures to those of the studies mentioned above. 
It is therefore possible that the overall improvement in renal function demonstrated by our 
results may be instead be due to significant improvements in renal function in a smaller 
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proportion of patients which made the overall relationship positive as opposed to negative; 
thereby satisfying the definition of ecological fallacy. However, this alternative explanation 
seems highly improbable considering the number of patients included in our study. 
 
The all-cause mortality rate for a follow-up period of up to 3.3 years was 7.4% for the total 
population.  
This figure follows similar findings published by other clinical studies which have reported 
all-cause mortality rates for patients with stage G3 CKD from as low as 6% after a follow up 
period of three years193 to as high as 32% and 51% after five and ten years respectively20. 
Although we cannot directly comment on the rate of cardiovascular mortality, evidence 
from other studies has shown varying figures from as low as 2% in a secondary care cohort 
after three years193 to 4% and 21% in a general population after thirteen and ten years 
respectively. 
 
Secondary care patients had a significantly increased risk of all-cause mortality. 
Our study shows that all-cause mortality rates for patients under primary care or secondary 
care are 4.3% and 10.8% respectively which confers to a significant increased relative risk of 
2.49 for patients in secondary care. Of the patients who died in secondary care compared to 
primary, the majority (90%) of patients had been seeing non-renal specialists although 
differences were not deemed to be statistically significant (RR=0.50, 95% CI = 0.23-1.06). 
This suggests that patients with CKD stage G3 who are at higher risk of all-cause mortality 
are more likely to be under secondary care but not necessarily under renal specialists and 
therefore that the increased risk of mortality in secondary care may be due to other non-
CKD related risk factors or co-morbidities in patients seeing non-renal specialists. The all-
cause mortality rate attributable to CKD stage G3 patients under renal specialists may be 
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quantified as 5.8% which is 1.5% more than primary care patients. This is similar to the rate 
of all-cause mortality rate of 6% from a patient cohort under nephrology care193 as 
previously mentioned above. 
 
The ESRD rate for a follow-up period of up to 3.3 years was 0.30 % for the total population.  
Our study demonstrated a very low rate of end-stage renal disease of only 0.74% for the 
complete follow up period of up to 8 years which reduced to 0.30% when restricted to 3.3 
years follow up. These figures are especially small in comparison to study with a ten year 
follow up of nephrology patients which published that just over one in four patients started 
dialysis22. However as the study patient population was from South Korea their results may 
not be generalisable to western populations which is demonstrated by a study showing a 
high rate of ESRD which outcompeted mortality risk in a population of patients from eastern 
Asia193.  
 
There was no significant difference between rates of ESRD between the different care 
groups. 
The incidence rate for our renal secondary care population was 1.68% after 3.3 years which 
although notably higher than the overall secondary care rate of 0.46% is in keeping with 
similar incidence rates reported in CKD stage G3 patients of 1.3-2% after 5 years and 4% 
after ten years20,21. Although there was a non-significant difference in risk of ESRD between 
primary and secondary care patients in our study, figures show lower rates in primary 
compared to secondary care of 0.14% and 0.46% respectively.  This is consistent with two 




Patients with CKD G3 are at greater risk of all-cause mortality than progression to ESRD. 
Similarly to results from other studies20,21, our findings support the risk of mortality being 
greater than the risk of ESRD in patients with CKD stage G3. This was true for all care settings 
which show that risk of ESRD was outcompeted by risk of mortality. We can quantify this as 
increased absolute risks of 7.10%, 4.17% and 10.34% for the total population, primary and 
secondary care respectively for a follow up period of 3.3 years. 
 
7.2 Clinical Impact 
The rationale behind our study was that NICE guidelines2 are currently based on poor 
evidence; especially those which pertain to when to refer patients for specialist care which 
on the whole recommend referral at stages 4-5 not stage G3. Here we revisit the advice 
provided by the National Institute of Clinical Excellence within the context of our findings to 
explore whether they support or refute current referral recommendations/practices. 
 
We have shown that within our study, patients in primary and non-renal secondary care 
showed overall improvements in renal function over time whilst secondary care patients 
under renal specialists showed an overall decline. This suggests that in primary care patients 
with stage G3 CKD are receiving good care from GPs which is not only able to reduce 
progression and maintain stable renal function for at least 2.84 years but perhaps also 
improve renal function in some patients. The lack of significant association between 
hypertension and eGFR in different care groups supports this and implies that overall 
hypertension was adequately controlled in all groups through the use of antihypertensive 
therapy. Our study therefore supports the current recommendation to refer patients for 
‘GFR less than 30 ml/min/1.73 m2 (GFR category G4 or G5), with or without diabetes’2 




On the other hand, we could not explain the worsening of renal secondary care patients via 
greater burdens of co-morbid hypertension, cardiovascular disease or known progressive 
renal diseases for the renal secondary care group as these were not significantly associated 
with eGFR.  However, if we also take into account the worse starting baseline renal function 
for secondary care groups especially renal patients it suggests that perhaps patients in 
secondary care under renal specialists were further along in their individual disease 
progression than primary care patients. Our results suggest that the start of deterioration 
occurs after 2.84 years. As the lack of association with comorbidities known to cause 
progression alludes to management being satisfactory in all care settings, we hypothesise 
that independently of existing comorbidities, patients with an increased propensity to 
decline have already been referred to secondary care by GPs. We also suggest that primary 
care management of CKD is able to defer renal decline in most patients for at least 2.84 
years. The NICE recommendations2 for identifying these patients as those who either suffer 
from a ‘sustained decrease in GFR of 25% or more, and a change in GFR category or 
sustained decrease in GFR of 15 ml/min/1.73 m2 or more within 12 months’, ‘known or 
suspected rare or genetic causes of CKD’, ‘hypertension that remains poorly controlled 
despite the use of at least 4 antihypertensive drugs at therapeutic doses’ or ‘suspected renal 
artery stenosis’ is supported by this hypothesis. The referral of RAS patients is also 
demonstrated by our study as 100% were in secondary care. However as there were still 
individual patients who progressed to ESRD under primary care, it is possible that some 
patients with progressive renal deterioration were not referred. 
 
It is clear from the overall trajectory of renal improvement and within primary and non-renal 
secondary care that patients who can be diagnosed with stage G3 CKD will not necessarily 
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progress and that a large proportion of patients may in fact improve over an average time 
period of 2.84 years. This brings into focus an additional question of whether the diagnostic 
definition of “abnormalities of kidney structure or function, present for more than 3 months, 
with implications for health”2 should have its time period of three months extended for 
patients with CKD stage G3 in the absence of other markers of renal dysfunction. One study 
using the K/DOQI81 staging criteria explored this relationship for patients with stage G3 by 
comparing rates of ESRD and improvement within diagnostic categories from 3 months to 12 
months194. It found that extending the category from 3 months up to 12 months only 
increased the incidence rate of ESRD from 4.2% in the 3 month cohort to 4.6% in the 12 
month cohort whilst the proportions of patients with improvement decreased. The observed 
0.1 ml/min/1.73 m2 per year increase in renal decline observed between 3 month and 6 
month cohorts was non-significant. This suggests that increasing the arbitrarily defined 
period for diagnosing patients with stage G3 CKD up to 6 months may reduce the number of 
patients undergoing unnecessary investigation for CKD without significantly affecting 
progression rates. However, the evidence from our study is not strong enough to support 
this recommendation. 
 
7.3 Limitations of the Study 
Capping of eGFR values greater than 60 ml/min/1.73 m2 meant that we had to calculate 
these values within our data set by using the MDRD equation on serum creatinine 
measurements. Ideally we would have used the exact equation used by the laboratory but 
this could not be provided within the timescale of this project. We cannot deny that by using 
MDRD calculated values we have introduced an element of bias into our data set. Although 
the MDRD equation is known to underestimate GFR ≥60 ml/min/1.73 m2 195, we do not know 
how this compares with the data provided from the laboratory so the true rates of eGFR 
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improvement/decline may have been over or underestimated. Despite this, we know that 
the overall relationships of slight improvement or decline are still valid as these trends were 
still present when using data with eGFR figures capped at 60 ml/min/1,73 m2. 
 
 Initially the data underpinning our study from secondary care was incomplete as it lacked 
information on comorbidities, and outcomes such as death or commencement of RRT. As 
previously mentioned this data was collected manually from outpatient clinic letters. 
Admittedly this method of data collection is not the most robust of data collection 
techniques as the data available to the collector was dependent on how individual 
consultants wrote their clinic letters. It is therefore likely that the burden of comorbidities 
within secondary care patients has been underestimated as information may have been 
missing from letters.  
 
Unfortunately we were unable to use portions of our data due to missing information within 
the data set. The most significant knock-on effect of this was the exclusion of albumin 
creatinine ratio from our baseline and longitudinal modelling as its inclusion excluded the 
majority of our patient records. As a well-known independent predictor of renal decline in 
CKD patients, this risk factor is important in identifying patients at increased risk of 
progression so being unable to account for this means that we were not able to compare the 
effects of albuminuria between care groups. This does not however affect the validity of our 
results on progression rates which was the main objective of our study. 
 
Due to the time constraints applied to this study, we were unable to quantify the duration of 
secondary care or frequency of visits to secondary care specialists. This means that we 
defined our primary and secondary groups based on a crude delineation of whether or not 
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patients had attended a specialist clinic or not. Although we know that any amount of 
secondary renal care is beneficial to patients with CKD, this research was conducted on 
patients with ESRD and therefore may not be generalisable to patients with stage G3 CKD. 
There may be a minimum amount of secondary care required before conferring benefit to 
patients in patients with stage G3 which we have therefore not been able to account for or 
explore with our study. This means we may not have compared the true effects of care on 
CKD stage G3 patients as some patients in secondary are may not have had any meaningful 
intervention at the time of their inclusion within the study. 
 
As our study compared primary and secondary care by using data from a single primary care 
practice, it is possible that results may not be generalisable to the whole of primary care. 
However, as the practice had twelve GPs we are likely to have captured the effects of 
potential differences in referral practices between doctors which, alongside a fairly large 
patient population, we believe supports our results as generalisable. 
 
7.4 Suggestions for Further Research 
We believe that we have identified an area which is severely lacking in evidence. Existing 
published studies often not only focus on patients with CKD stages G4-5 not stage G3 but the 
majority of studies focus on specific patient cohorts such as primary or secondary care which 
make direct comparisons between the two care settings difficult. 
 
Studies on patients with ESRD have already shown the benefits of secondary care referral by 
demonstrating reductions in the rate of decline as well as decreased mortality rates in 
individuals post-referral earlier to specialist care. However as we cannot generalise the 
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findings of these studies to patients with CKD stage G3 we suggest that similarly designed 
studies should be carried out which follow patients with CKD stage G3 pre and post-referral 
to secondary care so we can directly measure the potential benefits that secondary care can 
provide. Similar studies with longitudinal designs could also investigate the frequency of 
visits and the overall duration of care which could provide evidence on which to base criteria 
for the frequency of monitoring / follow-up in secondary care. 
 
Unfortunately our study was only able to make a crude comparison between patients who 
had been to secondary care and those who had not so could not shed any light on the 
impact of patient transitions between care groups. Guideline 1.5.4 from CG182 advises that 
patients referred to specialist care may be discharged back to primary care for ‘routine 
follow-up to take place at the patient's GP surgery rather than in a specialist clinic’. If doctors 
follow this advice, patients are therefore likely to transition between care settings: a variable 
which we have not managed to account for. In light of this, we propose that further studies 
could either study the patterns of transition between primary and secondary care and how 
this affects renal function for patients with CKD stage G3 or make less crude comparison 
than our study has. This could be done by comparing rates from periods when patients are 
known to have been in one care setting as opposed to an extended period of several years in 
which a patient was known to have visited a specialist at least once in the overall period. 
 
As previously mentioned some of the limitations of this study included being unable to 
account for albuminuria due to the missingness of the variable within the data set as well as 
limited generalisability from studying patients from only one GP practice and one hospital 
trust. Similar research should therefore be repeated on data sets which can include 
105 
 
albuminuria and also explore relationships in patients from a wide variety of different GP 
practices to increase the generalisability of results. 
 
During our longitudinal analysis we discovered an interesting association between albumin 
and diabetes which contradictorily seems to suggest that better nutritional status was 
associated with worse renal function of diabetic patients in primary care but improved renal 
function in patients in secondary care under renal specialists. Although this finding may be 
due to statistical artefact, a potential clinical explanation for this finding is beyond the 
current knowledge and understanding of the author but following a brief search for relevant 
literature, there seems to be limited evidence exploring albumin levels in diabetic patients 
with CKD which therefore underpins this as the final suggested area for future research. 
 
7.5 Conclusion 
Chronic kidney disease is a complex and diverse condition which affects a growing number 
of people worldwide. Its complications are numerous ranging from anaemia to metabolic 
bone disease and hyperparathyroidism.  Without intervention patients with CKD are at risk 
of developing end-stage renal disease requiring dialysis or transplantation or may instead 
suffer from cardiovascular events which result in patients being at increased risk of 
mortality. Whilst diabetes is the leading cause of ESRD, hypertension, vascular disease and 
albuminuria have relationships which are bidirectional in nature. They are both associated 
with causing or accelerating the progression of CKD and are also complications of renal 
dysfunction. Managing these risk factors through the use of antihypertensive agents, statin 
therapy and control of hyperglycaemia have been shown to improve patient outcomes by 
reducing CKD progression or reducing mortality risk. Specialists in secondary care aim to 
optimise the management of patient risk factors and this has already been shown to benefit 
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patients with ESRD by reducing rates of renal decline. Current UK guidelines from the 
National Institute of Clinical Excellence recommend referral of patients with CKD at stages 
G4-5 but these guidelines are based on ‘no evidence’ and the professional opinion of 
members of the Guideline Development Group only and other guidelines are not based on 
strong evidence. This proffered the question of whether patients with CKD stage G3 should 
be referred to secondary care or whether current management is adequate in primary care. 
Overall we found that for patients with CKD stage G3, renal function was stable and showed 
a slight improvement of 1.26 ml/min/1.73 m2 per year for an average follow up period of 
2.84 years. Patients in primary care showed slight rates of improvement in eGFR whilst renal 
secondary care patients declined overall which suggests that the care provided in primary 
care is able to maintain stable renal function and defer the start of deterioration. Renal 
secondary care patients showed a small overall rate of decline and had worse renal function 
at baseline which in the context of an overall population improvement implies that patients 
in renal care were potentially already further along in the CKD disease process than those in 
primary care. This also suggests that perhaps primary care is able to defer renal decline in 
CKD G3 patients for up to 2.84 years. 
Our findings support current NICE guidelines regarding the referral of patients to secondary 
care at stages G4-5 as on average CKD stage G3 patients did not progress. As patients in 
secondary care under renal specialist care had an overall decline in renal function, it 
suggests that patients with progression were already seeing nephrologists. This suggests 
that overall, the referral guidelines seem to be able to adequately identify patients at risk of 
progression. However as we did not conduct individual analyses we do not know to what 
extent this is assumption is valid. Furthermore, there is evidence which suggests that some 
progressing patients were not identified by general practitioners which may be inferred from 
the presence patients who progressed to end-stage renal disease in the primary care cohort. 
Further research on the effect of referral practices on CKD stage G3 patients should 
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therefore be conducted to identify other potential criteria for progression in this disease 
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APPENDIX A – Figures and Tables 










Mean 49.23 49.13 49.29 52.16 45.97 
Median 51.00 51.0 51.0 54.0 47.0 
SD 8.03 8.03 8.03 6.17 8.58 
Interquartile Range 43.0-56.0 43-56 44.0-56.0 49.0-57.0 39.0-53.0 
Range 30.0-59.0 30.0-59.0 30.0-59.0 31.0-59.0 30.0-59.0 
ACR 
(mg/mmol) 
Mean 3.775 6.51 1.28 2.01 8.84 
Median 0.61 0.84 0.50 0.45 1.68 
SD 10.10 13.98 2.46 7.14 14.87 








Mean 128.7 131.9 125.4 132.8 124.1 
Median 129.0 133.0 127.0 133.0 124.0 
SD 17.52 19.20 16.04 15.27 18.37 
Interquartile Range 117-140 120-146 116-136 123-143 113-136 




Mean 2.37 2.35 2.39 2.35 2.39 
Median 2.36 2.34 2.37 2.33 2.37 
SD 0.13 0.12 0.13 0.10 0.14 
Interquartile Range 2.30-2.43 2.28-2.40 2.31-2.44 2.29-2.39 2.31-2.45 




Mean 2.396 2.37 2.41 2.39 2.40 
Median 2.39 2.36 2.40 2.38 2.40 
SD 0.14 0.14 0.15 0.11 0.16 
Interquartile Range 2.32-2.47 2.31-2.44 2.33-2.49 2.32-2.46 2.32-2.49 
Range 1.61-3.16 1.86-3.01 1.61-3.16 2.03-2.80 1.61-3.16 
Albumin 
(g/L) 
Mean 41.35 41.42 41.30 42.05 40.53 
Median 42.0 42.0 42.0 42.0 41.0 
SD 3.48 3.61 3.40 3.01 3.85 
Interquartile Range 39.0-44.0 39.0-44.0 39.0-43.0 40.0-44.0 39.0-43.0 
Range 22.0-52.0 24.0-49.0 22.0-52.0 30.0-52.0 22.0-49.0 
ALP 
(IU/L) 
Mean 94.62 91.32 96.54 89.13 101.7 
Median 84.0 80.50 87.0 81.0 89.0 
SD 43.15 42.25 43.59 36.77 49.89 












Mean 1.12 1.07 1.16 1.12 1.12 
Median 1.12 1.07 1.15 .10 1.12 
SD 0.20 0.19 0.19 0.19 0.20 
Interquartile Range 0.99-1.25 0.93-1.20 1.01-1.29 0.99-1.25 0.99-1.25 




Table 20: Table of Complete Records 




























Figure 12: Baseline histograms of eGFR. ACR and ALP following log-transformation 
 
 
Figure 13: Histogram of residual values for the secondary care 
linear mixed effects model 
Figure 13: Residual plot for the secondary care mixed 
effects model 
Figure 16: Residual plot for the secondary care mixed 
effects model 
Figure 14: Histogram of residual values for the secondary care 
linear mixed effects model 
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APPENDIX B – R Script Examples 







































# model with all variables 
fit<-lm(data$eGFR~as.factor(data$Care)+data$Age+as.factor(data$Gender)+ 
          as.factor(data$Eth)+data$Hb+data$Adj.Calc+data$Alb+data$ALP+ 




# final model 
fit8<-lm(data$eGFR~data$Age+as.factor(data$Gender)+as.factor(data$Eth)+ 
           as.factor(data$Care)*as.factor(data$HTN)+data$Hb+data$Phos) 
  
# significance test 
anova(fit7,fit8) 
  
# residual diagnostics 
plot(fit8$fitted.values, fit8$resid, main="Residual Plot of Model", 
     xlab="Fitted Values",ylab="Residuals",xlim=c(35,60),ylim=c(-25,25)) 













Linear Mixed Effects Models 
all<-read.csv(file.choose()) 
library("nlme", lib.loc="C:/Program Files/R/R-3.2.3/library") 
  
# model with all variables 
fit<-lme(fixed = eGFR~Age+Gender+Eth+as.factor(Diagnosis)+ 
           (Day+Hb+as.factor(HTN)+Phos+as.factor(Diab)+(as.factor(Diab):Alb))*as.factor(Care), 




# final model 
fit10<-lme(fixed = 
eGFR~Age+Gender+Eth+as.factor(Diagnosis)+Hb+Alb+Phos+as.factor(hyp)+(Day+ 
          as.factor(Diab)+(as.factor(Diab):Alb))*as.factor(NewCare), random = ~Day|ID, 




# significance test 
anova(fit9,fit10) 
  
# residual diagnostics 
plot.lme(fit10) 
















# spaghetti plot of all patients 
ggplot(all,aes(x=Day,y=eGFR,group=ID))+ 
  geom_line()+ 
  theme_minimal()+ 
  xlab("Years")+ylab("eGFR (ml/min/1.73m^2)") 
  
# spaghetti plot of random sample (n=50) 
ids <- data.frame(sample(unique(all$ID), 50)) 
colnames(ids)<-"ID" 
samp<-all[all$ID %in% ids$ID,] 
  
ggplot(samp,aes(x=Day,y=eGFR,group=ID))+ 
  geom_line()+ 
  xlab("Years")+ylab("eGFR (ml/min/1.73 m^2")+ 
  theme_minimal()+ 
  theme(legend.position="none")+ 











Figure 9 Script 
library("mvtnorm", lib="C:/R/Rpackages") 
  
alpha1<-50 # intercept 
beta<- 1.834 # slope parameter for time 
SDU<-6.854 # std dev of random intercept 
SDV<-2.964 # std dev of random slope 
rho<-0.249 # correlation between random slope and intercept 
Vmat1<-matrix(c(SDU*SDU,rep(SDU*SDV*rho,2),SDV*SDV),2,2) 
  
n<-15 # number of samples required 
RE1<-rmvnorm(n,sigma=Vmat1) # simulate samples 




alpha2<-49.6 # intercept 
beta2<- 0.874 # slope parameter for time 
SDU<-6.854 # std dev of random intercept 
SDV<-2.964 # std dev of random slope 
rho<-0.249 # correlation between random slope and intercept 
Vmat2<-matrix(c(SDU*SDU,rep(SDU*SDV*rho,2),SDV*SDV),2,2) 
  
n<-20 # number of samples required 
RE2<-rmvnorm(n,sigma=Vmat2) # simulate samples 




alpha3<-37.6 # intercept 
beta3<- -0.171 # slope parameter for time 
SDU<-6.854 # std dev of random intercept 
SDV<-2.964 # std dev of random slope 





n<-20 # number of samples required 
RE3<-rmvnorm(n,sigma=Vmat3) # simulate samples 




for (i in 1:n) { 
  random1[i,]<-(RE1[i,1]+RE1[i,2]*years)+fixed1 
  random2[i,]<-(RE2[i,1]+RE2[i,2]*years)+fixed2 
  random3[i,]<-(RE[i,1]+RE3[i,2]*years)+fixed3 
} 
ylim<-c(5,90) 
xlim<-c(0,8)# make space for all the lines! 
plot(years,fixed1,type="l",col="red",lwd=3,xlim=xlim,ylim=ylim,xlab="Time 
(years)",ylab="eGFR (ml/min/1.73 m^2)", 
     main="Renal Function Over Time",xaxs="i") 
  
for (i in 1:n) { 
  lines(years,random1[i,],col="bisque") 
  lines(years,random2[i,],col="lightblue") 





legend("bottomleft",col=c("red","blue","green"),legend=c("Primary Care","Non-renal Care ", 
                                                       "Renal Care"),lwd=c(1,1,1),cex=0.75) 
  
 
